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This dissertation is focused on the interaction between the humoral (B cell) and cellular 
(T cell) arms of the adaptive immune system, and known autoantigens in patients with anti-
neutrophil cytoplasmic autoantibody (ANCA) vasculitis. ANCA vasculitis is characterized by 
vascular inflammation that leads to organ damage. Current treatment involves medications 
designed to induce disease remission, but many patients suffer from side effects including severe 
infection. We hypothesized that elucidating specific interactions between autoreactive 
lymphocytes and known autoantigens in patients would reveal targets for novel therapies that 
could halt the autoimmune response without side effects. 
In Chapter 1, I use high-resolution human leukocyte antigen (HLA) typing to identify 
alleles prevalent in our patients and demonstrate using Kaplan Meier estimates that carriage of 
HLA-DPB1*04:01 does not increase risk of relapse, contrary to previous results (1). Based on 
our independent serotype analysis, we hypothesize that carriage of HLA-DPB1*04:01 is a risk 
factor for patients with PR3-ANCA vasculitis (not MPO-ANCA vasculitis). Also addressed are 
significant differences between patients with MPO- and PR3-ANCA vasculitis, to clarify the 
rationale for focusing exclusively on MPO-ANCA vasculitis for the remainder of this 
dissertation. 
Chapter 2 focuses on potentially immunopathogenic regions of MPO. Patient 
autoantibody reactivity was assessed by enzyme-linked immunosorbent assay (ELISA) and anti-
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MPO447-461 antibodies were detected in 53% of patients. Epitopes were characterized using 
alanine scanning, circular dichroism, and solvent exposure experiments. Finally, in silico and in 
vitro binding studies confirmed the ability of MPO epitopes to bind patient HLA.  
In Chapter 3, I assess patient CD4+ T cell recognition of MPO epitopes. MHC II 
tetramers were created with patient HLA alleles and MPO epitopes, and used to stain patient 
cells. Patients demonstrated specific CD4+CD25intermediate T cell binding to tetramers and these 
cells secreted the pro-inflammatory cytokine IL-17A. TCR sequencing studies revealed clonally 
expanded autoreactive cells compared to controls, and some public TCR clones. Elucidation of 
these specific immune interactions will allow for new antigen-specific treatments using a variety 
of emerging techniques including chimeric antigen receptor (CAR) T cells, tolerogenic dendritic 
cells (DC), nanoparticle presentation of antigens, gene therapy, or removal of pathogenic T cells 
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PROLOGUE: ADAPTIVE IMMUNITY IN AUTOIMMUNE DISEASE 
Autoimmune diseases occur when the immune system misidentifies self as foreign and 
attacks, leading to inflammation and damage of healthy tissues. Since the 1950s when immune 
reactivity to self-proteins was first confirmed in patients with rheumatoid arthritis and later in 
systemic lupus erythematosus (2, 3), we have made enormous strides toward understanding the 
pathology of autoimmunity. However, many questions remain including the contributions of 
genetics vs. environment, why certain antigens are targeted by the immune system, and the 
pathogenic role of numerous immune cell subsets in these diseases. Most chronic diseases are 
determined by complex interactions between genetics and environmental influences (4), though 
the precise cause remains elusive.  
Leading hypotheses include a role for both genetics and environment in autoimmune 
disease etiology. One hypothesis proposes that sequence similarity between infectious agents and 
self-proteins (molecular mimicry) leads to misidentification by the immune system, though 
identifying microbial and self-peptide pairs has proved challenging (5). Another hypothesis is 
based on the temporal correlation between decreased infectious disease (due to improved 
hygiene), and the rising incidence of autoimmune diseases. The “hygiene hypothesis” proposes 
that a lack of childhood exposure to infectious agents, microorganisms, and parasites causes 
allergy and autoimmunity. This hypothesis is strongly supported by epidemiological data, and 
specific T cell responses (T helper 1 and T helper 2) have been implicated, though the underlying 
mechanisms remain unclear (6). In contradiction to the hygiene hypothesis is the “old friends” 
hypothesis that implicates the microbiome in allergy and autoimmunity, and suggests the need 
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for early exposure to a range of “friendly” microbes, not infectious pathogens to train the 
immune system (7). Diet, sanitation, antibiotic use, and parasite infection have been shown to 
alter human microbe exposure, and changes to these factors correlate with the rise in 
autoimmune prevalence. Epigenetic dysregulation has also been proposed as an explanation for 
autoimmunity because loss of epigenetic homeostasis leads to aberrant gene expression and 
immune dysfunction (8). Finally, it has been proposed that glycans in the immune system 
discriminate self from non-self and that altered glycosylation may explain autoimmunity, though 
analysis of the glycome has proven technically difficult (9). 
Autoimmune diseases have a significant impact on the United States in terms of 
individuals affected and healthcare costs. The National Institutes of Health estimates that 25-50 
million Americans suffer from more than one hundred distinct autoimmune diseases, costing 
nearly $100 billion in direct healthcare costs (10). Current treatments target the whole immune 
system, inflammation, or total T cell or B cell populations, rather than using antigen specific 
approaches to the immune response (11). Although existing treatments can be effective, 
autoimmune disease carries an extremely high cost to society including decreased quality of life, 
co-morbidities including depression and anxiety, lost productivity, and familial disruption due to 
the increased risk for women of childbearing age (12). Additionally, side effects of these 
medications include life-threatening opportunistic infections, long-term risk of malignancy, 
osteoporosis, diabetes mellitus, and cardiovascular disease (13, 14). Considering that the 
incidence of autoimmune disease is increasing over time (15), patients affected by these 
devastating diseases desperately need new, more effective treatments. 
This dissertation focuses on a group of autoimmune diseases collectively called ANCA 
vasculitis. A 2015 epidemiological report estimates the annual incidence at approximately 46-
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184/million with peak onset between 55 and 75 years of age (16). Though rare, this disease has 
been investigated for more than thirty years, and therapeutic breakthroughs for ANCA vasculitis 
may be adapted for efficacy in other autoimmune diseases. Additionally, ANCA vasculitis 
research has the advantage of exquisite autoantigen specificity compared to other autoimmune 
diseases. While type 1 diabetes (T1D), multiple sclerosis (MS), rheumatoid arthritis (RA), and 
systemic lupus erythematosus (SLE) have four or more identified autoantigens (17), most 
patients with ANCA vasculitis have autoantibody reactivity to one main autoantigen, MPO or 
PR3. This autoantigen specificity facilitates development of antigen-specific immunotherapy 
with increased probability of success compared to the other diseases. 
ANCA Vasculitis Pathogenesis 
Per the 2012 Chapel Hill Consensus Conference, ANCA vasculitis describes necrotizing 
small-vessel (arteries, arterioles, venules, veins) vasculitis with few or no immune deposits and 
the presence of myeloperoxidase specific anti-neutrophil cytoplasmic autoantibodies (MPO-
ANCA) or proteinase 3 specific anti-neutrophil cytoplasmic autoantibodies (PR3-ANCA) (18). 
These vasculitides are sub-classified into microscopic polyangiitis (MPA), granulomatosis with 
polyangiitis (GPA; formerly Wegener’s granulomatosis), and eosinophilic granulomatosis with 
polyangiitis (EGPA; formerly Churg-Strauss syndrome), (19). Depending on the location and 
severity, this blood vessel damage can lead to pulmonary hemorrhage, kidney 
glomerulonephritis, and eventually kidney failure, among many other symptoms (20). Untreated, 
patients with ANCA vasculitis develop severe organ damage most often in the lungs and/or 
kidneys (20). Even with existing therapies, patients are at serious risk for complications from 
disease relapse (21), the immunosuppressive therapy itself (22), and comorbidities including 
cardiovascular disease (23), diabetes, and malignancy (24). Consistent with other autoimmune 
diseases, the etiology and pathogenesis of ANCA vasculitis are influenced by a combination of 
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genetic factors and environmental exposures including infection, which also determine the 
characteristics of the innate and adaptive immune system for each patient.  
The vascular inflammation that is characteristic of ANCA vasculitis stems from 
inappropriate monocyte and neutrophil activation by patient ANCA binding to antigens such as 
MPO and PR3 at the surface of primed neutrophils (25, 26). Although the origin of the ANCA 
autoimmune response remains unclear, we know that ANCA are predominantly immunoglobulin 
G (IgG) autoantibodies secreted by plasma cells after their precursor B cells receive T cell help 
(27, 28). In the active injury phase, ANCA activated neutrophils degranulate, releasing toxic 
reactive oxygen species, enzymes, and factors that activate the complement system (26, 29). This 
begins an inflammatory amplification loop that results in destructive necrotizing lesions and 
endothelial injury (26, 30-32). In the next response-to-injury phase, neutrophil induced damage 
attracts monocytes that transform into macrophages and recruit T cells, ultimately leading to 
granulomatous inflammation (29, 33). Monocytes can also be activated directly by ANCA and 
produce cytokines including interleukin 8 (IL-8) and monocyte chemoattractant protein 1 (MCP-
1) that further recruit and activate immune system players (34-36). The consequence of this 
process is acute necrotizing injury to the vessel wall that either resolves or, in the case of severe 
injury or repeat antigen exposure, progresses to fibrosis and sclerosis of blood vessels (33). In 
patients with ANCA vasculitis, this pathogenic process occurs asynchronously in multiple 
organs, with each cycle taking approximately one to two weeks (29).  
 ANCA vasculitis can also be sub-classified based on autoantibody reactivity to 
target autoantigens MPO or PR3 (37, 38). ANCA binding to either of these self-antigens on 
circulating neutrophils and monocytes leads to blood vessel inflammation and damage as 
described above (39-42). It has been demonstrated that B cell secretion of ANCA induces 
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vascular damage, but autoantibody titers do not always correlate with disease activity (43), some 
healthy controls harbor naturally occurring anti-MPO antibodies (44), and some patients with 
identical disease symptoms do not have detectable levels of circulating ANCA (45). It follows 
that there must be additional immune dysfunction beyond the presence of autoreactive B cells 
and ANCA to fully explain onset and pathogenesis of disease in ANCA vasculitis. Possible 
explanations include T cell dysregulation, epitope specificity, avidity of the autoreactive cells, 
and/or dysregulation of antigen expressing cells.  
Major Autoantigens in ANCA Vasculitis 
 The two major target antigens in patients with ANCA vasculitis are MPO and PR3. 
Currently, IgG reactivity to MPO or PR3 measured by ELISA is the gold standard for diagnosing 
ANCA vasculitis (46, 47). Historically, ANCA vasculitis has also been diagnosed using an 
indirect immunofluorescence assay (46). It remains unclear which specific regions of these 
autoantigens are being targeted by the immune system in patients, though this information is 
important because it may reveal information about disease etiology. If the molecular mimicry 
hypothesis is correct, regions of the autoantigen identified by the immune system may share 
significant homology with a known pathogen and implicate that pathogen in disease onset. 
Additionally, knowledge of antigenic MPO and PR3 epitopes will inform the development of 
new immunotherapies, through re-introduction of immune tolerance to the epitopes.  
MPO is a peroxidase enzyme with antimicrobial properties synthesized in both 
neutrophils and monocytes and stored in granules and lysosomes respectively. MPO is released 
into the extracellular space during neutrophil degranulation (48). Myeloperoxidase is both 
microbicidal and damaging to normal tissue upon release, which implicates MPO in disease 
pathogenesis. Numerous studies have investigated epitope specificity of the autoimmune 
response to MPO using patient samples, mouse models of disease, and some in vitro models (49-
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56). PR3 is a serine protease enzyme with antimicrobial properties that is also expressed in 
neutrophil granulocytes. Previous work in our lab showed that patients have ANCA that bind not 
only to PR3 epitopes, but also to complementary PR3 (cPR3) (57). This finding is explained by 
the autoantigen complementarity theory that proposes the inciting antigen is not the self-antigen 
or a mimic, but a protein with complementary structure to the autoantigen (58). This finding was 
confirmed by another group who showed minimal patient PBMC response to PR3 peptide and a 
clear T cell response to the cPR3 peptide that was not present in healthy controls or with control 
peptide (59). 
One possible explanation for ANCA reactivity to MPO and PR3 is aberrant expression in 
patient neutrophils and therefore increased antigen availability. Indeed, studies have shown that 
both MPO and PR3, normally silenced in healthy controls, are expressed in mature neutrophils of 
ANCA patients (60, 61). Further investigation revealed that this dysregulation may be due to 
perturbed gene silencing, specifically via depleted chromatin modification histone H3 lysine 27 
trimethylation (H3K27) at both MPO- and PR3-encoding genes (62, 63). Recently, our group 
reported hypomethylation of genes that encode MPO and PR3 and increased autoantigen 
expression in patients with active disease (64). Additionally, increased deoxyribose nucleic acid 
(DNA) methylation at a specific CpG within PRTN3 (the gene that encodes PR3) was a predictor 
of sustained remission independent of serotype. Although the trigger for failed epigenetic gene 
silencing of MPO and PR3 remains unknown, these results implicate aberrant autoantigen 
expression in the pathogenesis and potentially onset of disease.  
Genetics of Autoimmunity and ANCA Vasculitis 
Genome wide association (GWAS) studies have implicated genetics in autoimmune 
disease by repeatedly identifying variants in the region of the genome that encodes HLA. The 
identification of HLA as a genetic risk factor specifically implicates the adaptive arm of the 
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immune system in disease, because HLA genes encode MHC receptors that play a key role in 
antigen presentation to T cells. MHC molecules are split up into two classes, MHC class I (MHC 
I) and MHC class II (MHC II) that share a similar function in that they present peptides to CD8+ 
and CD4+ T cells respectively (65). Generally, the presented peptides originate intracellularly for 
MHC I and exogenously for MHC II, however occasionally cross-presentation occurs; MHC I 
molecules presenting exogenous antigens, or MHC II molecules presenting degraded cytosolic 
proteins (66, 67). It is possible that MHC II molecules have access to intracellular antigen (MPO 
and PR3) peptides via macroautophagy, and therefore could present them to CD4+ T cells (68).  
In ANCA vasculitis specifically, GWAS studies have identified HLA-DP and HLA-DQ 
alleles that encode MHC II receptors (59, 69, 70). Additionally, HLA-DPB1*04:01 has been 
implicated in risk of relapse for ANCA vasculitis patients. For this reason, the T cell studies 
herein focus exclusively on CD4+ T cells and their interaction with MHC II-peptide complexes. 
MHC II molecules are primarily expressed by DCs, macrophages, and B cells, are assembled in 
the endoplasmic reticulum, and are loaded with class II-associated Ii peptide (CLIP). In order to 
present antigen to CD4+ T cells, HLA-DM facilitates exchange of the CLIP fragment for 
epitopes from proteins degraded in the endosomal pathway, and then the MHC molecule is 
transported to the plasma membrane (71). 
GWAS studies in ANCA vasculitis have also revealed genetic associations with the 
SERPINA1 (the gene for α(1)-antitrypsin) and PTPN22 (the gene for protein tyrosine 
phosphatase, non-receptor type 22) loci, with PRTN3, and with a single SNP near SEMA6A (the 
gene for semaphorin 6A) (59, 69, 70). It is possible that any of these variants directly influence 
the pathogenesis of ANCA vasculitis, though the mechanisms and extent of this influence remain 
to be elucidated.  
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B Cells and T Cells in Autoimmunity and ANCA Vasculitis 
The adaptive immune system consists of B and T lymphocytes (B and T cells) that 
identify and react to specific antigens (toxic or foreign molecules capable of inducing an immune 
response) via their surface antigen receptors called B cell receptors (BCR) and TCRs. BCRs and 
TCRs are encoded by random gene recombination: this process allows for broad recognition of 
extremely diverse pathogens, but occasionally results in the development of cells that recognize 
self-antigens (autoreactive cells). Rare autoreactive cells are usually controlled by intrinsic 
regulatory mechanisms, but there are documented cases where these safeguards fail and 
autoreactive cells persist (72-74).  
Tolerance describes the ability of the immune system to distinguish self from non-self 
and can be categorized into central and peripheral tolerance. Central tolerance is determined in 
the thymus and bone marrow, where naïve T cells and B cells are presented self-antigens and 
deleted based on inappropriate responses to those self-antigens before release into the periphery 
(108). Peripheral tolerance mechanisms include anergy (lack of functional response), deletion 
(apoptosis), or suppression by regulatory cells (109). Autoimmune disease occurs with failure of 
both central and peripheral tolerance mechanisms, as autoreactive cells have been repeatedly 
identified in the periphery of healthy individuals (110-113).  
One intrinsic mechanism regulates central T cell tolerance by determining the 
presentation of self-antigens to T cells during development in the thymus (75). Central T cell 
tolerance is mediated by the autoimmune regulator (Aire) transcription factor, which promotes 
promiscuous expression of self-antigens by medullary thymic epithelial cells (mTECs) (76-79). 
T cells that bind self-peptide MHC complexes with high-affinity are deleted in the thymus, 
preventing them from entering the periphery. However, some autoreactive cells escape this 
selection process and are managed by peripheral tolerance mechanisms including suppression by 
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naturally arising regulatory Tregs via a contact-dependent, cytokine-independent mechanism 
(80). One study looked specifically at Aire regulation of thymic MPO expression in mice and 
revealed that both Aire-dependent central deletion and regulatory T cell-mediated peripheral 
tolerance were important for establishing and maintaining tolerance to MPO (81). Mechanisms 
of autoreactive B cell regulation include deletion, receptor editing, and anergy induction (74). 
 TCRs interact with antigens presented in a 
specific manner by MHC receptors on antigen 
presenting cells (APCs). In contrast, BCRs are 
composed of immunoglobulin (Ig) molecules that 
directly acquire and react to antigens in their 
environment. Importantly, autoreactive B cells and T 
cells have been implicated in the pathogenesis of 
autoimmune diseases (82) including SLE (83, 84), T1D 
(85, 86), and RA (87, 88).  
In ANCA vasculitis, B cells are implicated in 
disease pathogenesis by the presence of anti-MPO or 
anti-PR3 antibodies and by the ability of Rituximab (anti-B cell therapy) to ameliorate disease in 
patients (89). Our group demonstrated the importance of regulatory B cells (Bregs) by showing 
that after B cell depletion by Rituximab, patients on low maintenance immunosuppression who 
repopulated their CD5+ Bregs (90) with low or decreasing percentage had a shorter time to 
relapse compared to patients with normalized CD5+ B cells or higher immunosuppression (91). 
Additionally, we showed that in active disease CD5+ Bregs that produce anti-inflammatory 
cytokine IL-10 are decreased, and that the presence of more Bregs (as in disease remission) 
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correlates with decreased ANCA titer (90). Another group reported that peripheral B cells in 
patients with ANCA vasculitis display higher expression of CD38 and lower expression of CD5 
during disease activity, compared to increased CD25 and CD86 expression in remission (92). 
Other B cell defects include a numerical deficiency of Bregs and a reduction of memory B cells 
(Bmem) during active disease (93). Additionally, mouse models of ANCA vasculitis have 
demonstrated that ANCA alone can cause disease (41, 94).  
T cells have been implicated in ANCA vasculitis pathogenesis based on their presence at 
sites of inflammation (95-98), and the discovery that CD4+ T cell help is required to produce 
ANCA (99). Reported T cell defects in patients include persistent CD4+ T cell activation (100-
102), dysfunctional regulatory T cells (103-105), and an expansion of a suppression resistant, 
proinflammatory, antigen experienced T cell population (105). Chapter 3 includes a detailed 
discussion of the existing literature describing T cell defects in ANCA vasculitis.  
New Therapeutic Strategies 
Despite the basic understanding that autoimmune diseases are caused by inappropriate 
adaptive immune responses to self-antigens, decades of extensive research, and development of 
new targeted therapies (ex. Rituximab), we are still unable to clinically predict who will enter 
stable remission off therapy or cure patients with these diseases (106). Currently the most 
effective therapies for patients with ANCA vasculitis and other autoimmune conditions are 
immunosuppressive agents that destroy entire populations of immune cells and put patients at 
high risk for severe complications (107). There is a dire need for antigen-specific therapies that 
halt autoimmune reactivity in patients without depleting the cells necessary to fight infection. As 
mentioned previously, ANCA vasculitis is a model disease for the development of new antigen-
specific treatments due to the specificity of the autoimmune response (to MPO or PR3) 
compared to the numerous antigens that have been identified in other diseases.  
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Antigen-specific immunotherapy involves reintroducing immune tolerance that is lost in 
autoimmunity. Proposed methods to reintroduce tolerance are similar to allergen specific 
immunotherapies used to desensitize the immune system to allergens (17). One method involves 
nasal administration of antigen directly; another delivers antigenic epitopes bound to 
nanoparticles. Researchers have attempted to reintroduce lost immune tolerance in mouse models 
of numerous autoimmune conditions using both of these methods (114-116), and with nasal 
administration in type 1 diabetes patients (117) with varied success. If we can elucidate the 
specific interactions between autoreactive lymphocytes and the autoantigens in ANCA vasculitis, 
we may be able to harness these methods to reintroduce immune tolerance to MPO and PR3.  
Another category of antigen-specific immunotherapy involves selectively deleting 
autoreactive cells, inducing anergy in those cells, or generating regulatory cells to suppress the 
autoimmune response. One of these methods involves designing CAR T cells with TCRs that 
target autoreactive cells. One group designed chimeric autoantibody receptor (CAAR) T cells to 
treat the autoimmune blistering disease pemphigus vulgaris. These CAAR-T cells exhibited 
cytotoxicity against autoreactive B cells expressing anti-DSG3 BCRs on their surface and 
specifically eliminated these cells in vivo (118). If a specific marker of autoreactivity for patient 
B and/or CD4+ T cells can be identified in ANCA vasculitis, CAR T cells can be designed to 
selectively target cells with that marker. Alternatively, several methods have been developed to 
generate antigen specific regulatory T cells, which may be harnessed to replace the faulty Tregs 
in patients with ANCA vasculitis (119). One method modifies the TCR to target specific 
peptides presented by HLA, though these cells are HLA restricted. Alternatively, chimeric 
antigen receptor modified Tregs are HLA unrestricted but can exhibit bystander suppression.  
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Tolerogenic dendritic cell therapy has also been proposed as a method to reintroduce T 
cell tolerance in autoimmunity. Antigen presentation by DCs without proper co-stimulation leads 
to T cell anergy, and may be used to halt autoreactive T cell responses. Phase 1 clinical trials in 
rheumatoid arthritis and type 1 diabetes have confirmed the safety of dendritic cell 
immunotherapy and are paving the way for development of these new treatments (120, 121). If 
we can identify pathogenic T and B cell epitopes within the known ANCA vasculitis 
autoantigens, these epitopes will inform development of these antigen-specific immunotherapies 
for patients. 
Central Hypothesis 
B cells and T cells have been repeatedly implicated in autoimmunity broadly and ANCA 
vasculitis specifically. However, the specific interactions between these cells and known 
autoantigens largely remain poorly understood. The central hypothesis of this body of work is 
that specific interactions between B cells, T cells, and known autoantigens MPO and PR3 play 
an important role in both onset and pathogenesis of disease. If we can identify and understand 
these interactions, we can harness them to develop new therapies for patients with ANCA 
vasculitis. This hypothesis can be broken down into several sub-hypotheses. The first, addressed 
in Chapter 1, is that patients with ANCA vasculitis are carriers of specific HLA alleles that put 
them at increased risk for disease onset and increase relapse rates. In this chapter I identify HLA-
DPB1 and HLA-DRB4 alleles that are more prevalent in patients than controls, though we do not 
see any increase in relapse rate for carriers of HLA-DPB1*04:01, contrary to previous reports 
(1). This is the only sub-hypothesis and chapter that includes PR3-ANCA patients, due to 
significant differences between disease serotypes and the merits of studying MPO-ANCA 
patients independently. 
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The second sub-hypothesis, addressed in Chapter 2, is that previously identified 
pathogenic MPO epitopes are exposed to solvent, bound by patient autoantibodies and MHC II 
receptors, and that binding will be dependent on secondary structure and specific residues of the 
epitope. These studies demonstrate that 53% of patients have anti-MPO447-461 antibodies and that 
binding is dependent on both the alpha helix structure of the epitope and two specific amino 
acids Lysine488 and Isoleucine456. Interestingly, these studies also reveal that one end of the T 
cell epitope MPO435-454 is exposed to solvent but B cell epitope MPO447-459 is buried within MPO. 
Finally, in silico and in vitro binding studies confirm binding of MPO447-459 and MPO435-454 to 
patient HLA.  
The third sub-hypothesis, addressed in Chapter 3, is that patient CD4+ T cells will bind 
previously identified pathogenic MPO epitopes. These autoreactive CD4+ T cells will be 
CD25intermediate, pro-inflammatory, memory cells with decreased TCR diversity (indicating clonal 
expansion) compared to controls, and some TCRs may be shared between patients. In this 
chapter, I demonstrate that patients with MPO-ANCA vasculitis who are carriers of HLA-
DBP1*04:01 and/or HLA-DRB4*01:01 have CD4+ T cells that bind both T cell epitope MPO435-
454 and B cell epitope MPO447-461. These cells are CD25
intermediate, pro-inflammatory (IL-17A 
secretion), memory cells (CD45RO expression), that are clonally expanded compared to control 





CHAPTER 1: CARRIAGE OF HLA-DPB1*04:01 DOES NOT INCREASE RELAPSE 
RISK IN PATIENTS WITH ANCA-VASCULITIS 
Introduction 
GWAS studies in ANCA vasculitis have consistently shown an association between HLA 
and disease (59, 69, 70). More specifically, three separate GWAS studies identified HLA-DP as 
a risk allele in ANCA vasculitis (59, 69, 70). Additional studies have described associations 
between specific HLA alleles (HLA-DPB1*04:01 and HLA-DRB1*15) and disease (1, 122). 
Hilhorst et al. investigated carriage of HLA-DPB1 and risk of relapse in a cohort of European 
patients and found that carriage of HLA-DPB1*04:01 was associated with an increased risk of 
relapse regardless of disease serotype (1). Cao et al. reported that Caucasians with PR3-ANCA 
had 2.2-fold higher odds of carrying DRB1*1501 than controls, that African Americans with 
PR3-ANCA had a 73.3-fold higher odds of having HLA-DRB1*15 alleles than community 
based controls, and that many carry the HLA-DRB1*15:01 allelic variant of Caucasian descent, 
rather than the HLA-DRB1*15:03 allelic variant of African descent (122).  
It is not surprising that associations have been found between specific HLA alleles and 
disease in patients with ANCA vasculitis because HLA alleles encode the shape and charge of 
the MHC peptide-binding pocket and therefore determine the size, shape, and charge of antigens 
that can be recognized, bound, and presented to T cells by APCs. Additionally, HLA has been 
previously associated with numerous other autoimmune diseases including T1D (123), celiac 
disease (124) and SLE (125). This association between HLA and disease further supports a role 
for T cells in the pathogenesis of ANCA vasculitis.  
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In addition to the need for new therapies, there remains a need for prognostic indicators 
for patients with ANCA vasculitis. Given the severe side effects of current immunosuppressive 
therapy, a biomarker that identifies patients at increased risk for relapse would aid clinicians in 
determining which patients to treat and which to monitor. The rituximab versus 
cyclophosphamide/azathioprine for AAV (RAVE) trial was one of several studies that found 
serial PR3-ANCA titers to be useful in anticipation of severe relapses in a subset of patients 
(126), but prognosis indicators that are useful for all patients with ANCA vasculitis have yet to 
be identified. It is possible that carriage of specific HLA alleles may be used to predict risk of 
relapse in patients with ANCA vasculitis (1). 
In this chapter, I investigated the prevalence of specific HLA alleles in our cohort of 
patients, and the influence of HLA-DPB1*04:01 carriage on risk of disease relapse. We 
hypothesized that carriers of HLA-DPB1*04:01 would be at increased risk of relapse in a 
combined cohort of MPO- and PR3-ANCA vasculitis patients. Despite numerous phenotypic 
similarities between European and North American patient populations, it is possible that there 
are enough regional differences to yield a dissimilar result in our cohort compared to the Hilhorst 
et al. cohort (1). Contrary to the previous study, we found no increased risk of relapse for carriers 
of HLA-DPB1 when including patients with both MPO- and PR3-ANCA vasculitis. When 
assessing patients by serotype we determined that carriage of HLA-DPB1*04:01 may incur some 
risk for patients with PR3-ANCA vasculitis, but appears to have no effect on those with MPO-
ANCA vasculitis. 
Materials and Methods 
Study Design 
The objective of this study was to delve further into the strong association between HLA 
and ANCA vasculitis (59, 69, 70) by performing high-resolution, sequence-based HLA typing in 
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a large population of patients with ANCA vasculitis. Patients with ANCA vasculitis were 
enrolled at University of North Carolina at Chapel Hill clinics and followed in the Glomerular 
Disease Collaborative Network (127, 128). Patients were recruited according to the guidelines of 
the Institutional Review Board (study no. 97–0523) by the University of North Carolina Office 
of Human Research Ethics. Study subjects gave informed, written consent and participated 
according to University review board guidelines. 
Patient Cohort 
Patients were diagnosed according to the Chapel Hill Consensus Conference (18, 129). 
Patient charts were reviewed by clinicians to confirm disease activity status, periods of relapse, 
periods of remission, and serotype, prior to analysis. ANCA serotypes were assessed by indirect 
immunofluorescence and antigen-specific PR3 and MPO ELISAs (130). Disease activity was 
determined by the 2003 Birmingham Vasculitis Activity Score (BVAS) in conjunction with 
clinical signs of activity. In this study, patients with a BVAS of 0 and no clinical or laboratory 
evidence of active disease were considered to be in remission. Active disease was defined as a 
BVAS >0 with clinical and/or laboratory evidence of disease (131). Patients were excluded from 
the study if they were ANCA negative by ELISA, had suspected or confirmed drug-induced 
forms of ANCA vasculitis, or had overlapping diseases. Patients were selected for this study 
based on availability of DNA samples for HLA sequencing. 
HLA Sequencing 
High-resolution HLA typing was performed by our collaborators at the Institute for 
Immunology and Infectious Diseases (IIID) in Perth, Western Australia, which is accredited by 
the American Society for Histocompatibility and Immunogenetics (ASHI) and the National 
Association of Testing Authorities (NATA). All the steps in the pipeline from sample prep to the 
reporting were quality assessed and tracked using an accredited Laboratory Information and 
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Management System (ELab). Automated liquid handlers and data analysis were performed using 
accredited proprietary software applications HLA allele caller and HLA Analysis Suite 
(Murdoch University, Western Australia). Briefly, HLA loci were PCR amplified for Class I (A, 
B, C Exons 2 and 3) and Class II (DQB1, Exons 2 and 3; DRB, DQA1 and DPB1, Exon 2) MHC 
genes using MID tagged primers were optimised to minimize allele dropouts and primer 
bias. Amplified DNA products from unique MID tagged products were pooled in equimolar 
ratios and prepared for Illumina sequencing. Libraries were quantified by qPCR and quality 
assessed on the Agilent Bio analyser or Tape Station. Normalized libraries were then sequenced 
using Illumina MiSeq platform (MiSeq V3 600-cycle kit, 2X300bp paired end reads). The 
quality filtered data was demultiplexed by MID tags, merged, and the alleles were called using 
an HLA allele caller software that minimises the influence of sequencing errors. Alleles were 
called using the latest IMGT HLA allele database as the allele reference library. The HLA 
analysis reporting software, performed comprehensive allele balance checks, and assigned 
putative allele calls for ambiguous results and contamination checks on the final dataset. 
Statistical Analysis 
Categorical measures were summarized as number and percent, and continuous measures 
were reported as mean and standard deviation or median and interquartile range, if not normally 
distributed. Comparison of demographics and clinical parameters between groups by HLA-
DPB1*04:01 genotype status (null, heterozygous, or homozygous) were done using Fisher Exact 
tests for categorical variables and Kruskal-Wallis tests for continuous variables. Kaplan-Meier 
estimates and log rank test were used to assess differences in time to relapse of HLA-
DPB1*04:01 genotypes in all ANCA vasculitis patients and in ANCA serotypes independently. 
Proportional hazards models with each variable of interest were used to assess differences 
between relapsing and non-relapsing patients, with hazards ratios, p-values, and 95% confidence 
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intervals reported. Cohort allele prevalence was calculated by number of patient alleles over total 
possible alleles and presented as a percent. Patient prevalence was calculated as the number 
heterozygous and homozygous patients for alleles of interest, over total number of patients and 
presented as a percent.  
Results 
HLA allele prevalence differs between MPO- and PR3-ANCA vasculitis 
One way to assess HLA prevalence in a cohort of patients is to consider the frequency of 
each allele compared to the total number of possible alleles (2 per patient). To unambiguously 
identify specific HLA variants, we performed HLA typing for our cohort of ANCA vasculitis 
patients (n=249) and found that the two most prevalent class II alleles in our cohort of ANCA 
vasculitis patients were HLA-DPB1*04:01 (n=260, 52%) and HLA-DRB4*01:01 (n=176, 35%). 
These alleles are slightly overrepresented in our patient cohort compared to the general 
population of Caucasians in the United States (41% for HLA-DPB1*04:01 and 32% for HLA-
DRB4*01:01 based on data from the Allele Frequency Net Database www.allelefrequencies.net). 
In MPO-ANCA patients alone, HLA-DPB1*04:01 (n=110, 42%), HLA-DRB4*01:01 (n=108, 
41%), HLA-A 02:01 (n=88, 33%), and HLA-DQA1*03:01 (n=79, 30%) were the most prevalent 
alleles (Table 1.1). 
 
Table 1.1 HLA allele prevalence in MPO-ANCA vasculitis. Top three most prevalent alleles for 
each HLA gene in our cohort of MPO-ANCA vasculitis patients (n=132) including number of 















































































In PR3-ANCA patients, HLA-DPB1*04:01 (n=150, 64%), HLA-DRB4*01:01 (n=68, 
29%), HLA-A*02:01 (n=66, 28%), and HLA-DQA1*01:02 (63, 27%) were the most prevalent 
alleles (Table 1.2). Interestingly, of the HLA genes with more than three identified alleles, the 
top three most prevalent alleles are consistent between MPO- and PR3-ANCA vasculitis patients 
for HLA-A and HLA-B (encode MHC I receptors), as well as HLA-DPB1 and HLA-DRB3 
(encode MHC II receptors). For others, like HLA-DQA1 the same three top alleles are the same 
but in a different order of prevalence.  
 
Table 1.2 HLA allele prevalence in PR3-ANCA vasculitis. Top three most prevalent alleles for 
each HLA gene in our cohort of PR3-ANCA vasculitis patients (n=117) including number of 
patients (n) and percent (%) of total alleles (n=234) for each. 
 
Homozygous carriers of HLA-DPB1*04:01 are white and most have PR3-ANCA vasculitis 
Based on previous GWAS studies in ANCA vasculitis and the Hilhorst et al. report on 
HLA-DPB1 carrier risk (1), we investigated carrier frequency of the HLA-DPB1*04:01 allele in 
our cohort. This analysis revealed that of 117 PR3-ANCA vasculitis patients included in the 
analysis, 96 patients or 82% were heterozygous or homozygous carriers of HLA-DPB1*04:01. In 
contrast, only 85 of 132 MPO-ANCA vasculitis patients (64%) were carriers of HLA-
DPB1*04:01. Our patient carrier frequencies were similar to the Hilhorst et al. cohort of 174 
patients (90% PR3 carriers, 63% MPO carriers), though our carrier frequency in PR3-ANCA 












































































Table 1.3 shows patient cohort characteristics by HLA-DPB1*04:01 carrier status. 
Homozygous carriers of HLA-DPB1*04:01 differed from heterozygous carriers and/or non-
carriers by race, follow-up time, ANCA serotype, diagnosis, estimated glomerular filtration rate 
(eGFR), and organ involvement. Homozygous carriers of HLA-DPB1*04:01 were most often 
white and were more likely to have PR3-ANCA vasculitis. Homozygous carriers also had the 
longest follow up time, highest prevalence of GPA diagnosis, and highest eGFR. Additionally, 
they were more likely to have upper respiratory, joint, and neurological disease involvement 
compared to heterozygous and non-carriers.  
Carriage of HLA-DPB1*04:01 Does Not Increase Relapse Risk in a Combined Cohort 
In our combined cohort of 117 PR3-ANCA and 132 MPO-ANCA patients, we do not see 
an increased risk in time to relapse when stratified by HLA-DBP1*04:01 carrier status (p=0.27, 
Figure 1.1). This result is in direct contradiction to the Hilhorst et al. study, which reported a 
stepwise effect of HLA-DPB1*04:01 carriage in a cohort of 344 MPO- and PR3-ANCA 
vasculitis patients (1). They showed in their combined cohort of European patients (Dutch and 
German) that homozygous carriers were at the highest risk for relapse, followed by heterozygous 
carriers, and then non-carriers.  
Carriage of HLA-DPB1*04:01 May Influence Risk in Patients with PR3-ANCA Vasculitis 
When stratified by ANCA subtype, MPO-ANCA vasculitis patients showed no difference 
in risk of relapse (Figure 1.2A), regardless of HLA-DPB1*04:01 carrier status (p=0.63). In 
contrast, PR3-ANCA vasculitis patients showed a trend toward increased risk of relapse in 
homozygous HLA-DPB1*04:01 carriers as compared to heterozygous carriers and non-carriers 
(Figure 1.2B, p=0.07). This PR3-ANCA vasculitis result closely resembles the Hilhorst et al. 
German cohort relapse analysis, likely explained by their cohort composition (80% PR3-ANCA 




Table 1.3. Cohort demographics by HLA-DPB1*04:01 carrier status. Characteristics of the UNC 
ANCA vasculitis cohort overall and according to HLA-DPB1*04:01 status. Differences between 
the three groups were evalulated using Fisher Exact test for categorical variables and Kruskal-




Figure 1.1. Kaplan Meier curve of relapse by HLA-DBP1*04:01 carrier status. Cohort (n=249, 
log-rank test=0.2732) includes both MPO- and PR3-ANCA patients. Patients are null (0, solid 





Figure 1.2. Kaplan Meier curves of relapse by HLA-DBP1*04:01 carrier status and ANCA 
serotype. (A) Kaplan Meier curve of relapse for MPO-ANCA patients alone n=132 (B) Kaplan 
Meier curve of relapse for PR3-ANCA patients alone n=117. Patients are null (0, solid line), 
heterozygous (1, dashed line) or homozygous (2, dotted line) for HLA-DPB1*04:01. 
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 We also evaluated characteristics of patients who relapsed compared to those who did not 
relapse over a period of 15 years, and assessed the influence of these characteristics on the time 
to relapse by HLA-DPB1*04:01 status (Table 1.4). We did not find statistically significant 
predictors of relapse when assessing age, gender, eGFR, race, highest BVAS, HLA-DPB1*04:01 
status, ANCA serotype (MPO or PR3), or diagnosis (MPA, GPA, or Renal Limited disease).  
 
Table 1.4. Characteristics of ANCA vasculitis cohort according to relapse status. n=207 patients 
went into complete remission (on or off therapy) and were eligible to relapse. A proportional 




Contrary to previous work, in our cohort of MPO- and PR3-ANCA vasculitis patients, 
carriers of the DPB1*04:01 allele did not have an increased probability of relapse compared to 
non-carriers. This contradictory result is likely explained by cohort composition, as our cohort 
consisted of 53% MPO-ANCA compared to 22% in the previous study’s combined cohort (1). 
Based independent serotype analyses, we conclude that HLA-DPB1*04:01 carrier status may be 
informative for PR3-ANCA patients, but is not predictive of relapse in a combined or MPO-
ANCA only cohort. This finding is consistent with previous GWAS results that HLA-DPB1 is a 
Characteristics of relapsing vs. non-relapsing AAV Patients (n=207) 
Characteristic No Relapse (n=79) Relapse (n=128) Hazard Ratio  
Age, mean ± SD Years 56.95 ± 17.72 56.57 ± 18.36 1.00 (0.99, 1.01) 
Male 49(62.0%) 61(47.7%) 0.80(0.56, 1.13) 
eGFR, mean ± SD  35.07 ± 33.08 (n=78) 46.44 ± 31.82(n=124) 1.00(1.996, 1.01) 
Race (non-white) 18(22.8%) 21(16.4%) 0.77(0.48, 1.23) 
Highest BVAS, mean ± SD  11.78 ± 6.50 (n=49) 11.44 ± 6.26 (n=116) 1.03(1.00, 1.06) 
HLA-DPB1*04:01 Status       
     Homozygous (n=67) 21(26.6%) 46(35.9%) 1.21(0.77, 1.91) 
     Heterozygous (n=82) 32(40.5%) 50(39.1%) 1.37(0.88, 2.13) 
     Noncarrier (n=58) 26(32.9%) 32(25.0%) ref 
ANCA Serotype       
     PR3-ANCA (n=98) 34(43.0%) 64(50.0%) ref 
     MPO-ANCA (n=109) 45(57.0%) 64(50.0%) 0.82(0.58, 1.17) 
Diagnosis       
     Lim (n=33) 18(22.8%) 15(11.7%) ref 
     GPA (n=79) 24(30.4%) 55(43.0%) 1.51(0.85, 2.68) 
     EGPA(n=5) 3(3.8%) 2(1.6%) 1.04(0.24, 4.56) 
     MPA (n=90) 34(43.0%) 56(43.8%) 1.48(0.83, 2.61) 
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risk factor for patients with PR3-ANCA only (59). Less likely explanations for this contradictory 
result include differences in race (18% non-white patients in our cohort vs. 0% previously),  
baseline eGFR (lower in our cohort), or presence of renal involvement (90% in our cohort vs. 
50% previously) in our cohort compared to Hilhorst et al. (1). Additionally, there may be 
geographical differences in disease phenotype between our cohorts that are not captured by 
measures included in the analysis. Although carriage of HLA-DPB1*04:01 did not predict risk of 
relapse in our cohort, it is possible that there are additional risk alleles carried by our patients that 
either independently, or in combination with HLA-DPB1*04:01, provide prognostic value for 
our patients. Future studies should investigate the value of additional HLA alleles as a biomarker 
of disease. 
Despite similarities in the pathogenesis of MPO- and PR3-ANCA vasculitis, there are 
significant differences between the two serotypes at every level, from autoantigen recognition 
(37, 38) to genetics (59) and frequency of disease relapse (21). This suggests that evaluation of 
MPO- and PR3-ANCA vasculitis patients together may mask important differences between the 
two groups, especially at the level of T cell autoantigen interaction. Indeed, the difference in risk 
of relapse conferred by carriage of HLA-DPB1*04:01 between MPO-ANCA and PR3-ANCA 
patients was hidden in our combined cohort analysis and only revealed with independent 
serotype analyses. Additional reported differences between MPO- and PR3-ANCA vasculitis 
include autoantibody class (IgG in MPO, IgG and IgA in PR3) (132), prevalence of MPA and 
GPA (PR3 commonly GPA, MPO commonly MPA or EGPA) (133), geographic location (PR3 
in northern areas, MPO in southern areas) (134), and environmental risk factors (PR3 Ross River 
virus and staphylococcus aureus, MPO silica and hydralazine) (135-137).  
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Unlike MPO-ANCA vasculitis, investigation of PR3-ANCA vasculitis pathology has 
been hindered by the lack of reproducible animal models of disease, in part due to differences 
between human and murine neutrophil PR3 expression (138). Therefore, much of what we know 
about PR3-ANCA vasculitis comes from in vitro experiments and human studies. This has 
prevented investigation into specific cell-epitope interactions that have been thoroughly studied 
using mouse models of MPO-ANCA vasculitis. Given how much more we know about MPO 
epitope specificity and the significant differences in disease pathogenesis between disease 
serotypes, the remainder of this dissertation will focus solely on MPO-ANCA vasculitis. Ideally, 
successful methods used to elucidate cell-epitope interactions in MPO-ANCA vasculitis will be 
amenable to future PR3-ANCA vasculitis studies.  
27 
 
CHAPTER 2: PATIENT ANCA AND HLA ALLELES BIND MPO EPITOPES  
Introduction 
While B cells and their secretion of ANCA undoubtedly play a role in vascular damage, 
some observations from patients complicate our understanding of their specific role in the 
induction of immune dysregulation. These observations include: autoantibody titers that do not 
always correlate with disease activity (43), healthy controls which harbor naturally occurring 
anti-MPO antibodies (44), and some patients with disease symptoms without detectable levels of 
circulating ANCA (45). One possible explanation for these observations is that epitope 
specificity of ANCA determines their pathogenicity. 
To address this, previous work in our lab used a highly sensitive epitope excision/mass 
spectrometry approach (MALDI-TOF/TOF-MS) to determine epitope specificity of anti-MPO 
antibodies in ANCA vasculitis patients and healthy controls (49). This study identified a linear 
epitope, MPO447-459, that was of particular interest due to the presence of patient anti-MPO447-459 
ANCA reactivity during periods of disease activity that declined upon clinical remission, and 
was not identified in healthy controls (49). In mice, Ooi et al. screened overlapping MPO 
peptides of 20 amino acids and identified MPO409-428 as an immunodominant MPO T-cell 
epitope based on its ability to induce focal necrotizing glomerulonephritis upon immunization in 
C57BL/6 mice (50). The human homolog of this epitope (MPO435-454) overlaps our previously 
identified linear MPO epitope (MPO447-459) by eight amino acids. Additionally, they found that 
transfer of MPO409-428 specific CD4
+ T cell clones into Rag1-/- mice in combination with LPS or 
anti-GBM antibodies induced disease (50). Recently, Chang et al. also identified MPO431-439 as a 
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pathogenic CD8+ T cell MPO epitope and demonstrated that co-transfer of MPO431-439 specific 
CD8+ T cells into Rag1-/- mice exacerbated disease (139). This epitope is just a few amino acids 
downstream from the CD4+ T cell epitope identified in mice, and our B cell epitope identified in 
humans, which suggests that we may have collectively identified an immunodominant region of 
MPO.  
In this chapter, we set out to further investigate the properties of this region of MPO for 
its potential role in disease pathogenesis. Our hypothesis was that previously identified 
pathogenic MPO epitopes (MPO447-459 and MPO435-454) are exposed to solvent, bound by patient 
autoantibodies and MHC II receptors, and that binding will be dependent on secondary structure 
and specific residues of the epitope. ELISA studies, alanine scanning, solvent exposure studies, 
and MHC binding assessments were used to determine structure, location, exposure, and binding 
capabilities of this region to inform future cellular experiments.  
Materials and Methods 
Study Design 
The objective of these experiments was to understand the immunogenic potential and 
biochemical properties of previously identified MPO epitopes MPO447-459 and MPO435-454. 
Patients with ANCA vasculitis were enrolled at University of North Carolina at Chapel Hill 
clinics and followed in the Glomerular Disease Collaborative Network (127, 128). Patients, 
healthy controls, and disease controls (SLE and PR3-ANCA) were recruited according to the 
guidelines of the Institutional Review Board (study no. 97–0523) by the University of North 
Carolina Office of Human Research Ethics. Study subjects gave informed, written consent and 
participated according to University review board guidelines. Patients were chosen for ELISA 
studies based on availability of repeat serum samples.  
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Patient Cohort 
Patients were diagnosed according to the Chapel Hill Consensus Conference (18, 129). 
Patient charts were reviewed by clinicians to confirm disease activity status, periods of relapse, 
periods of remission, and serotype. ANCA serotypes were assessed by indirect 
immunofluorescence and antigen-specific PR3 and MPO enzyme-linked immune-absorbent 
assays (ELISA) (130). Disease activity was determined by the 2003 Birmingham Vasculitis 
Activity Score (BVAS) in conjunction with clinical signs of activity. In this study, patients with 
a BVAS of 0 and no clinical or laboratory evidence of active disease were considered to be in 
remission. Active disease was defined as a BVAS >0 with clinical and/or laboratory evidence of 
disease (131). Patients were excluded from the study if they were ANCA negative by ELISA, 
had suspected or confirmed drug-induced forms of ANCA vasculitis, or had overlapping 
diseases. Patients with systemic lupus erythematosus (SLE) and healthy controls (HC) were used 
as comparator groups.  
ELISA Studies 
Demographic features of the study subjects are shown in Table 2.1. A total of 979 serum 
samples were tested by ELISA for reactivity to native MPO and MPO447-461 (Biomatik). Control 
samples included serum from 93 healthy controls, 24 patients with systemic lupus 
erythematosus, and 48 patients with PR3-ANCA with half in disease remission. The remaining 
serum samples were acquired from 66 patients with MPO-ANCA at multiple time points 
spanning disease course (>4 samples n=45, >3 samples n=50) as determined by clinical 
manifestations of disease and conventional assays. In addition, longitudinal autoantibody 
responses to the B cell epitope MPO447-461 were measured in 51 patients over time (average 
follow-up time of cohort was 3.86 years) by ELISA.  
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Table 2.1. Demographics summary for Patient ELISA cohort.  
 
ELISA studies utilized a peptide with the addition of two amino acids (MPO447-461 instead 
of MPO447-459) to increase solubility of the peptide. Solid white ELISA plates (Grenier) were 
coated with 0.01mM peptide coating solution made in 0.5M carbonate-bicarbonate buffer at pH 
9.3 and incubated overnight at 4° C.  Plates were blocked in Dulbeccos’s PBS (Gibco) with 1% 
goat serum (Gibco) and 0.5% Tween20 (Fisher Scientific) for 2 hours at 37° C.  The serum 
samples were diluted in blocking buffer (1:100) and incubated at 37° C for 1 hour.  Goat anti-
human with alkaline phosphatase conjugate secondary antibody specific to Ig (H+L) (Millipore) 
(1:10,000) was also diluted in blocking buffer then incubated for 1 hour at room temperature and 
detected using CDP-Star substrate in Roche Detection Buffer with enhancer in a Tecan Infinite 
M200 Pro plate reader programmed for luminescence. For cross-sectional studies, the peak value 
is represented from each patient (Figure 2.1A).  
MPO ANCA serum samples were screened for MPO titers regardless of disease activity 
or previously reported titers. The MPO ANCA kits were purchased from INOVA and all the 
samples were run in duplicate, following the recommended protocol. Absorbance values were 
measured by a Tecan Infinite M200 Pro plate reader (Life Sciences). 
Alanine Scanning 
To determine the residues required for binding peptide binding to patient IgG, each 
amino acid in MPO447-461 (RKIVGAMVQIITYRD) was replaced with an alanine. All peptides 
were run in triplicate with positive (known positive patient for RKIV) and negative (healthy 
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serum and secondary alone) controls consistent across plates, with one patient per plate. 
Chemiluminescence was measured using a Tecan Infinite M200 Pro plate reader (Life Sciences). 
Circular Dichroism 
The spectra were the average of four scans obtained by collecting data at 0.2 nm intervals 
from 260 to 190 nm, with a response time of 2s and a bandwidth of 1 nm. The raw CD data were 
adjusted by subtracting a buffer blank. Peptide concentration in all samples was 100 uM in 10 
mM phosphate buffer, pH 7.4 containing 150 mM NaCl. 
Solvent Exposure 
The atomic coordinates were obtained from the Protein Data Bank (entry 1CXP). Solvent 
accessibility was calculated using the 'rolling ball' algorithm and the GETAREA software (140). 
This algorithm uses a sphere (of solvent) of a particular radius (typically 1.4 Å) to 'probe' the 
surface of the molecule. Residues are considered to be solvent exposed if the ratio value exceeds 
50% and to be buried if the ratio is less than 20%. 
In Silico Predictions 
In silico predictions were made by the Immune Epitope Database (www.iedb.org) to 
identify antigen candidates (15 amino acid length maximum based on algorithm limits) for the 
HLA alleles carried by our patients.  
In Vitro Binding Studies 
Assays to quantitatively measure peptide binding to HLA-DRB4*01:01 and HLA-
DPB1*0401 (class II) MHC molecules are based on the inhibition of binding of a high affinity 
radiolabeled peptide to purified MHC molecules, and were performed essentially as described 
elsewhere (141-143). In brief, 0.1-1 nM of radiolabeled peptide was co-incubated at room 
temperature with 1 nM to 1 µM of purified MHC in the presence of a cocktail of protease 
inhibitors. Following a two day incubation, MHC bound radioactivity was determined by 
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capturing the MHC/peptide complexes on L243 (anti HLA-DR) or B7/21 (anti HLA-DP) 
antibody coated Lumitrac 600 plates (Greiner Bio-one, Frickenhausen, Germany), and measuring 
bound cpm using the TopCount (Packard Instrument Co., Meriden, CT) microscintillation 
counter. In the case of competitive assays, the concentration of peptide yielding 50% inhibition 
of the binding of the radiolabeled peptide was calculated. Under the conditions utilized, where 
[label]<[MHC] and IC50 ≥ [MHC], the measured IC50 values are reasonable approximations of 
the true Kd values (144, 145). IC50 values under 100 are indicative of high affinity binding to 
HLA, values between 100 and 1000 represent good binding pairs, and values greater than 1000 
indicate lack of binding to the HLA.  Each competitor peptide was tested at six concentrations 
covering a 100,000-fold dose range. As a positive control, the unlabeled version of the 
radiolabeled probe was also tested in each experiment. 
Human Myeloperoxidase structure was obtained from the Protein database using PDB 
code 5FIW and visualized using PyMOL by Schrödinger. 
Statistical Analysis 
Descriptive statistics included number with percentage, mean with standard deviation, 
and/or median with interquartile range. Differences between groups were compared using 
Fisher’s exact tests for categorical measures. T tests, Wilcoxon rank sum tests, or Kruskal-Wallis 
tests were used for continuous measures, based on the number of groups being compared and 
whether or not the data was normally distributed. Sign rank tests were used for paired 
comparisons. GraphPad Prism was used to generate figures (Version 7, GraphPad Software, La 




Patient ANCA bind MPO447-461 most often at disease onset 
Based on previous work in our lab that identified MPO447-461 as a region of interest (49), 
we set out to assess patient ANCA reactivity to this region in a large cohort of patients. Fifty-
three percent of tested patients (n=27/51) were positive for anti-MPO447-461 autoantibodies at 
least once during their disease course (Figure 2.1A), most often at disease onset (Figure 2.1B). 
To understand any potential impact of therapy on anti-MPO447-461 reactivity, patients who were 
positive for anti-MPO447-461 were compared to those who were negative for reactivity, and we 
found that negative samples had a higher incidence of treatment prior to sample collection 
(Figure 2.1C). We also compared patients who were positive for anti-MPO447-461 ever to those 
who were negative for reactivity to MPO447-461 and PR3 controls to identify any potentially 
confounding differences in cohort characteristics (Table 2.2). In addition to treatment differences 
shown in Figure 2.1C, there were some differences in organ involvement and duration of follow 
up between groups. Anti-MPO447-461 positive ever patients had a longer duration of follow up and 
more upper respiratory and joint involvement compared to anti-MPO447-461 never positive 
patients. Therefore, the true prevalence of anti-MPO447-461 autoantibodies may be 
underrepresented in our cohort. 
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Figure 2.1. Anti-MPO447-461 autoantibody is detectable in 53% of patients by ELISA most often 
at onset. (A) Measured serum or plasma anti-MPO447-461 ELISA reactivity from healthy controls 
(HC, n=93), patients with PR3-ANCA vasculitis (n=48), patients with systemic lupus 
erythematous (SLE, n=24), and patients with MPO-ANCA vasculitis (n=51), normalized to a 
positive control. Threshold of positivity was determined by the average of healthy control 
samples plus two standard deviations and is indicated by the grey dashed line. (B) Reactivity of 
20 samples collected at onset (active disease) paired with a remission sample from the same 
patient, normalized to a positive control. (C) Analysis of onset samples revealed that anti-




Table 2.2. Comparison of ELISA Study Patient Demographics by anti-MPO447-461 reactivity. 
Groups include MPO447-461 positive ever, MPO447-461 positive never, and PR3-ANCA vasculitis 
patient controls. 
 
MPO-ANCA vasculitis patients in this cohort had serial serum samples that were used to 
assess correlation between anti-MPO447-461 and disease activity. We identified a close correlation 
36 
between anti-MPO447-461 reactivity and disease activity in a portion of patients (results from 
illustrative patient shown in Figure 2.2A), while others demonstrated anti-MPO447-461 reactivity 
only at disease onset (Figure 2.2B).  
 
Figure 2.2. Anti-MPO447-461 reactivity correlates with disease activity or disease onset in 
patients. Temporal analysis of patient MPO447-461 ELISA reactivity compared to BVAS scores. 
(A) Patient anti-MPO447-461 reactivity correlates with disease activity assessed by BVAS score. 
(B) Patient anti-MPO447-461 reactivity correlates with disease onset, not disease activity assessed 
by BVAS score. Plotted MPO447-461 reactivity values are reflective of MPO447-461 (RxKIV) values 
minus corresponding Anti-MPO447-461scramble (RxIKA) negative control reactivity to normalize 
between samples.  
 
Furthermore, there was no correlation between ANCA reactivity to whole MPO and 
MPO447-461 (Figure 2.3) suggesting that ANCA reactivity to the B cell epitope MPO447-461 is 
specific, not just a readout for ANCA reactivity to whole MPO. 
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Figure 2.3. Anti-MPO447-461 reactivity to MPO447-461 does not correlate with reactivity to whole 
MPO. Correlation between whole MPO reactivity and MPO447-461 reactivity for all samples tested 
(n =766 samples from 66 patients). 
 
MPO447-461 is buried and MPO435-454 is exposed to solvent 
We sought to understand the dynamics of how B and CD4+ T cells are able to interact 
with these epitopes. Utilizing the crystal structure of human MPO, we found that MPO435-454 and 
MPO447-461 are adjacently located on the same alpha helix (Figure 2.4A & 2.4B). Solvent 
accessibility predictions were then made based on the crystal structure of MPO using the 'rolling 
ball' algorithm and GETAREA software (Figure 2.4C). 
The solvent exposure analysis confirmed that the B cell epitope MPO447-461 is buried 
inside MPO. Although we would expect both epitopes to be exposed to solvent and therefore to 
patient ANCA (allowing antibody reactivity), antigenic epitopes buried inside self-proteins have 
been previously reported (140). In contrast, and as we would expect, the T cell epitope MPO435-
454 has residues that are exposed to solvent. Collectively, the data demonstrate that the majority 
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of this region MPO435-461 is buried within MPO (illustrated in figure 2.5), which would preclude 




Figure 2.4. MPO435-461 is located on an alpha helix that is mostly buried within MPO. Cartoon 
models of (A) MPO447-461 and (B) MPO435-454 highlighted in blue demonstrate alpha-helical 
structure of the region. Models were generated using Pymol and human MPO crystral structure 
(PDBID:5FIW). (C) MPO447-461 is buried, while part of MPO435-454 is exposed to solvent. 
Accessibility to solvent of each amino acid determined using human MPO crystal structure 
(PDBID:1CXP). Residues are considered to be solvent exposed if ratio value > 50%, and buried 
if the ratio value < 20%. 
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Figure 2.5. Sphere model demonstrating exposed portions of region MPO435-459 based on crystal 
structure. Blue color demonstrates location of MPO435-459  region. Model was generated using 
crystal structure (PDBID:5FIW) and Pymol software.  
Lysine448 and Isoleucine456 are required for ANCA binding to MPO447-461 
Considering that buried epitopes require conformational changes to become exposed to 
the immune system, we further investigated the B cell epitope MPO447-461.  These studies were 
designed to identify the critical amino acids that mediate binding of anti-MPO ANCA to 
MPO447-461 with alanine scanning experiments. Peptides for MPO447-461 were generated using 
sequential substitutions of alanine for each amino acid in the peptide. Sera from eight anti-
MPO447-461 positive patients were used to assess reactivity to each peptide. These experiments 
revealed that peptides with alanine substitutions for Lysine448 and Isoleucine456 demonstrate 
significantly decreased serum reactivity to the peptide (Figure 2.6). At neutral pH lysine is 
hydrophobic, polar, and positively charged and therefore plays an important role in structure. 
Alanine replacement of this amino acid is likely to disturb the structure of MPO447-461 due to its 
non-polar and mildly hydrophobic nature. Also hydrophobic, isoleucine is limited by bulkiness 
near the protein backbone that limits conformation and is very non-reactive. Perhaps the small 
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size of the alanine replacement is enough to disturb MPO447-461 structure and inhibit ANCA 
binding.  
 
Figure 2.6. Alanine scanning of MPO447-461 reveals Lysine448 or Isoleucine456 are required for 
binding to patient ANCA. Experiments were performed in triplicate with eight previously 
positive patients by ELISA for MPO447-461. The positive control (PC) was the same highly 
positive serum included on every plate and the same healthy control (HC) was included on every 
plate. IKA is an MPO447-461 scrambled control and a secondary antibody only (2° Only) control 
was also used. 
 
The alpha helix structure of MPO447-461 is required for ANCA binding 
Amino acid substitutions often cause changes in the secondary structure; therefore, 
circular dichroism experiments were performed to examine any resulting structural changes. 
These experiments revealed that alanine substitutions for Lysine448 or Isoleucine456 resulted in a 
disrupted alpha helical structure, which likely explains the altered autoantibody binding (Figure 
2.7). This same alpha helix disruption was observed for the MPO447-461scramble epitope used as a 
control throughout numerous experiments. Therefore, these data indicate that linear epitope 
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MPO447-461 is buried within the molecule and that patient ANCA binding to this epitope is 
dependent on the alpha-helix structure.  
Figure 2.7. Circular dichroism experiments reveal loss of alpha-helical structure with alanine 
substitutions at K448 or I456. RKIVGAMVQIITYRD is the amino acid sequence for MPO447-461 
and IKAVRIYIGDVMRQT is the sequence for MPO447-461scramble. Spectra were the average of 
four scans obtained by collecting data at 0.2 nm intervals from 260 to 190 nm, with a response 
time of 2 seconds and a bandwidth of 1 nm. 
Patient HLA alleles are predicted to bind regions of MPO 
In addition to patient ANCA reactivity to specific regions of MPO, we wanted to study T 
cell binding to MPO. Due to the specificity of antigen recognition by TCRs, we first needed to 
investigate the ability of patient HLA encoded MHC II alleles to bind MPO epitopes of interest. 
Unbiased in silico binding predictions from the Immune Epitope Database identified five 
putative MPO epitopes (15 amino acids in length based on algorithm limitations) with their 
respective HLA binding partner(s) and identified HLA-DRB4*01:01 as the predicted binding 
partner for our previously identified B cell epitope MPO447-461 (Table 2.3). Additionally, a 15 
amino acid long section of the mouse immunodominant MPO epitope published in Ooi et al. 
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(2012) was included in this analysis (mouse MPO413-427), and was predicted to bind HLA-
DRB5*01:01. 
 
Table 2.3. MPO epitopes and in silico predicted HLA binding partners. AUC is Area Under the 
Curve and Predicted Percentile Rank is calculated based on how the predicted affinity of that 
peptide for that allele ranks in a very large set of peptides randomly extracted from UniProt.  
 
HLA-DPB1*04:01 and HLA-DRB4*01:01 bind MPO447-461 and MPO435-454 in vitro 
The seven epitopes from in silico prediction, in addition to the previously identified T 
cell epitope MPO435-454 and scrambled control epitope MPO447-461scramble were assessed for 
binding to HLA using an in vitro competitive binding assay. The B cell epitope MPO447-461 and 
control epitope MPO447-461scramble bound both HLA-DPB1*04:01 and HLA-DRB4*01:01 with 
high affinity (Table 2.4). In contrast, the T cell epitope MPO435-454 bound HLA-DRB4*01:01 
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Immune recognition of self-proteins plays an important role in the early pathogenesis of 
autoimmune disease. Identifying specific epitopes within these self-proteins that immune cells 
react to is critical not only to further elucidate disease pathogenesis, but also for the development 
of new therapies for patients. Additionally, we may be able to identify patterns of epitope 
autoreactivity that will lead to the identification of previously unrecognized autoantigens. Our 
analysis of previously reported regions of MPO revealed the buried nature of B cell epitope 
MPO447-461, residues required for binding of patient ANCA, the alpha helical structure of 
MPO435-461, and the ability of patient HLA to bind and present both the B cell and T cell 
epitopes.  
Although the buried nature of MPO447-461 is surprising, it is not unprecedented. An 
epitope identified by anti-glomerular basement membrane (GBM) antibodies is also buried and 
requires conformational changes of the antigen to be revealed (146). The buried nature of these 
epitopes implicates a substantial disruption to normal protein structure to reveal the antigenic 
epitopes. The possibility of buried antigenic peptides is also supported by several proposed 
mechanisms for the breakdown in peripheral tolerance that allow adaptive immune system 
recognition of self-proteins. These mechanisms include conformational changes that reveal new 
epitopes, overproduction of the self-antigen, post-translational modifications, or cellular 
mislocation of proteins (147, 148).  
The Immune Epitope Database was used to predict regions of MPO and their HLA 
binding partners. As expected, not all of the epitopes identified by in silico predictions bound 
effectively to HLA during in vitro binding experiments, however both MPO447-461 and MPO435-
454 had moderate to strong binding affinity for HLA-DPB1*04:01 and HLA-DRB4*01:01. These 
two epitopes were particularly interesting based on prior reports from both human and mouse 
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studies. Mouse MPO409-428, which corresponds to human MPO435-454, was reported as an 
immunodominant CD4+ T cell epitope, and mouse MPO431-439 (human MPO457-465) was reported 
as a pathogenic CD8+ T cell epitope (50, 115, 139). These two epitopes overlap with our 
previously published B-cell epitope (MPO447-459), discovered by epitope excision mass 
spectrometry, by eight and three amino acids respectively (or eight and five amino acids with 
MPO447-461 used for the studies reported herein, Figure 2.8).  
Figure 2.8. Human myeloperoxidase model based on crystal structure. (PDBID:5FIW) 
Highlighted regions are as follows; dark blue - MPO435-454 (Ooi et al. 2012), purple- MPO447-459 
(Roth et al. 2013), light blue - MPO457-465  (Chang et al. 2017), gold - overlap between 
highlighted regions. The active site heme of myeloperoxidase is colored red.  
Further strengthening the importance of this region of MPO is a previous study, which 
utilized human-mouse chimeric MPO molecules. These studies demonstrated that sera from ten 
of fourteen patients bound the same region where these epitopes are located (51). However, there 
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are other MPO epitopes of interest on both the light (52) and heavy chains (49, 51, 53-56) that 
should be investigated using the methods described here.  
Given patient autoantibody reactivity and MHC binding to previously identified epitopes, 
this region of MPO may be a strong candidate for reintroduction of immune tolerance. Mouse 
MPO409-428 (corresponds to human MPO435-454, our T cell epitope) has been used to reintroduce 
tolerance by nasal insufflation in a mouse model of focal necrotizing glomerulonephritis. 
Insufflation of this peptide afforded protection before onset of disease and partially ameliorated 
established autoimmune disease (115). This suggests that new antigen-specific therapies 
targeting this region of MPO may provide some relief for patients with MPO-ANCA vasculitis.  
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CHAPTER 3: AUTOREACTIVE CD4+ T CELLS ARE PRO-INFLAMMATORY 
MEMORY CELLS THAT BIND MPO 
Introduction 
As mentioned in Chapter 2, despite convincing evidence that ANCA are pathogenic (39), 
the existence of naturally occurring anti-MPO antibodies in healthy individuals (44) and ANCA 
negative patients (45) complicate our understanding of ANCA vasculitis pathogenesis. Another 
possible explanation for this discrepancy is that T cells play an important role in disease 
pathogenesis beyond just B cell help via cytokine secretion. In addition to genetic associations 
with HLA, there is a significant body of work that implicates T cells in the pathogenesis of 
autoimmune diseases and ANCA vasculitis. First, T cells have been detected in the kidneys, 
lungs, and nasal biopsies in patients with ANCA vasculitis (149). Additionally, Sanders et al. 
showed an increase in soluble IL-2 and CD30 in the plasma of patients that correlated with 
disease activity (150), and Abdulahad et al. demonstrated an increase of circulating memory T 
cells in the urine of patients with active disease (151). Studies also suggest that CD4+ T cells 
mediate MPO-ANCA production in patients (152). These findings represent just a snapshot of 
decades of research that make a clear case for the role of T cells in the pathogenesis of MPO 
ANCA vasculitis.  
There is also a body of work that has suggested a pathogenic role for a pro-inflammatory 
subset of T cells, called Th17 cells, in glomerulonephritis (153). Numerous studies in mice have 
linked Th17 responses to organ specific autoimmune inflammation (154), rheumatoid arthritis 
(155, 156), and inflammatory bowel disease (IBD) (157), therefore they likely also play a role in 
ANCA vasculitis. Additionally, studies have demonstrated that immune dysregulation in 
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autoimmunity can be attributed to dysfunction of regulatory T cells (Treg) (72), hyperactivation 
of effector T cells (Teff) (73), or an imbalance of cell subsets (158). T cell studies in ANCA 
vasculitis report conflicting results of increased (103) and decreased Treg frequency (104, 159), 
as well as normal (160) and decreased Treg function (103, 104, 159). Additionally, effector T 
cell resistance to Treg suppression was reported in patients (73). Recent studies from our lab 
demonstrated increased but dysfunctional regulatory T cells in combination with an expanded 
pro-inflammatory, IL-17 producing, CD25intermediate population that is resistant to Treg cell 
suppression in patients (105). 
Though most studies in ANCA vasculitis have focused on CD4+ T cell subsets, CD8+ 
cytotoxic T cells have also been implicated in the pathogenesis of autoimmunity (161). 
Consistent with previous CD4+ T cell findings, CD8+ T cells are more activated (100, 162), they 
have been identified in the kidney (98, 163), and their numbers correlate with eGFR at 
presentation in patients with ANCA vasculitis (163). Another study that performed 
transcriptional profiling of CD8+ T cells found an association between poor prognosis and 
expansion of a CD8+ memory T cell population in patients with ANCA vasculitis (164). 
Additionally, a mouse model of ANCA immunopathogenesis demonstrated that MPO specific 
CD8+ T cells exacerbated disease (139). However, CD8+ T cells differ from CD4+ T cells in that 
they recognize peptides presented by MHC I instead of MHC II receptors, and they can kill cells 
directly via perforin and granzymes.  
CD4+ T cells identify antigens in tissue and peripheral blood via TCR binding to specific 
receptors on the surface of antigen presenting cells (APCs) called major histocompatibility 
complex (MHC). APCs bind antigen to form a peptide-MHC II complex that is presented to T 
cells and bound by the TCR. This binding is specific to the structure of the TCR, the antigen, and 
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the MHC molecule, and is the first step in the initiation of an immune cascade designed to 
destroy the pathogen. The rarity of autoreactive T cells, specificity and low affinity of these 
TCR-peptide-MHC interactions, and elusive autoantigens in many autoimmune diseases have 
hindered the study of this process in disease. However, recent enhancements to MHC II 
tetramers allow direct investigation of this interaction at a single cell level (165). 
TCR sequencing is used to assess the clonality of T cells. Random gene rearrangement 
during development generates enormous TCR diversity within an individual, making it very 
unlikely that T cells with identical TCRs arise from independent T cell clones (166, 167). Clonal 
expansion of T cells occurs upon recognition of antigen and results in differentiation of clones 
with various effector and memory phenotypes to effectively fight pathogens. In autoimmunity, 
one recent study described a restricted TCR repertoire with public (shared) TCR alpha chains in 
a group of patients with type 1 diabetes (168), while another reported that the TCR repertoire in 
patient synovium is dominated by a small number of highly expanded clones in rheumatoid 
arthritis (169), suggesting clonal expansion of rare autoreactive T cells. Restricted clonality and 
the presence of public TCRs in autoimmunity suggest a role for an immunodominant epitope in 
the initial loss of immune tolerance. Additionally, identification of clonally expanded, 
autoreactive, public (shared) TCR sequences that are not found in non-pathogenic CD4+ T cells 
may inform development of TCR directed therapy. 
In Chapter 3, I investigated the ability of patient CD4+ T cells to bind B cell epitope 
MPO447-461 and T cell epitope MPO435-454, introduced in Chapter 2. We are predominantly 
interested in CD4+ helper T cells because of previously described GWAS and HLA sequencing 
studies that implicated HLA alleles that encode MHC II receptors (HLA-DP and HLA-DQ 
alleles) in disease. I tested the hypothesis that autoreactive CD4+ T cells in MPO-ANCA 
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vasculitis are CD25intermediate pro-inflammatory cells that bind specific regions of the respective 
autoantigen (B cell epitope MPO447-461 and/or T cell epitope MPO435-454), that these cells are 
clonally restricted compared to control T cells, and that there are some public or shared TCRs 
between patients. Using MHC II tetramers, flow cytometry, and TCR sequencing, I attempted to 
identify a signature of CD4+ T cell autoreactivity that distinguishes these cells from non-
pathogenic CD4+ T cells. The ability to precisely identify autoreactive cells will inform the use 
of chimeric antigen receptor techniques to selectively target autoreactive cells, or design antigen 
specific regulatory T cells to replace the faulty Tregs in patients (119). Furthermore, if this T cell 
autoreactivity signature includes unique surface marker expression, apheresis may be used to 
selectively remove pathogenic cells (170).  
Materials and Methods 
Study Design 
The objective of these experiments was to understand the interaction between MPO 
epitopes MPO447-461 and MPO435-454 and patient CD4
+ T cells. Patients with ANCA vasculitis 
were enrolled at University of North Carolina at Chapel Hill clinics and followed in the 
Glomerular Disease Collaborative Network (127, 128). Patients and healthy controls were 
recruited according to the guidelines of the Institutional Review Board (study no. 97–0523) by 
the University of North Carolina Office of Human Research Ethics. Study subjects gave 
informed, written consent and participated according to University review board guidelines.  
Patient Cohort 
Patients were diagnosed according to the Chapel Hill Consensus Conference (18, 129). 
Patient charts were reviewed by clinicians to confirm disease activity status, periods of relapse, 
periods of remission, and serotype prior to analysis. ANCA serotypes were assessed by indirect 
immunofluorescence and antigen-specific PR3 and MPO enzyme-linked immune-absorbent 
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assays (ELISA) (130). Disease activity was determined by the 2003 Birmingham Vasculitis 
Activity Score (BVAS) in conjunction with clinical signs of activity. In this study, patients with 
a BVAS of 0 and no clinical or laboratory evidence of active disease were considered to be in 
remission. Active disease was defined as a BVAS >0 with clinical and/or laboratory evidence of 
disease (131). Patients with suspected or confirmed drug-induced forms of AAV or overlapping 
disease were excluded. Patients that were ANCA negative by ELISA and healthy controls were 
used as comparator groups.  
Demographic features of the study subjects (Table 3.1). For tetramer studies, patients 
were chosen based on HLA sequencing status as carriers of HLA-DPB1*04:01 and HLA-
DRB4*01:01. Our patient cohort consisted of homozygous (n=4 for HLA-DRB4*01:01, n=6 for 
HLA-DPB1*04:01), heterozygous (n=8 for HLA-DRB4*01:01 and n=8 for HLA-DPB1*04:01), 
and null (n=5 for HLA-DRB4*01:01 and n= 4 for HLA-DPB1*04:01) patients for each HLA. 
Non-HLA-DPB1*04:01 alleles for heterozygous and null patients are included in Table 3.2. 
Patients that carried both HLA were tested with both sets of tetramers. Healthy controls with 
(n=2 for HLA-DRB4*01:01, n=4 for HLA-DPB1*04:01) and without (n=3 for HLA-
DRB4*01:01, n=1 for HLA-DPB1*04:01) the HLA alleles of interest, and heterozygous ANCA 




Table 3.1. Demographics summary for tetramer studies cohort. Healthy controls were reasonably 
well matched to patients on age, gender, and race. *There were three missing values for BVAS. 
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Table 3.2. Non-HLA-DPB1*04:01 alleles in tetramer studies cohort. List of alleles other than 
*04:01 of null (n=5) and heterozygous (n=8) patients included in tetramer studies.
Figure 3.1. Amino acid sequence alignment of mouse and human myeloperoxidase. Mouse 
MPO409-428 (light grey), human MPO435-454 (blue), human MPO447-461 (blue), and human MPO447-
461scramble (dark grey). Amino acid differences between mouse and human epitopes shown in red. 
MHC II Tetramer Studies 
Tetramers were generated (Benaroya Institute, CA) for both HLA-DPB1*04:01 and 
HLA-DRB4*01:01 as previously described (171) by exogenously loading recombinant protein 
with the following MPO epitopes: MPO447-461 (RKIVGAMVQIITYRD) and MPO435-454
(PRWDGERLYQEARKIVGAMV). Tetramers created with MPO447-461 scramble 
(IKAVRIYIGDVMRQT) were used as a control for both HLA alleles. To assess specificity of 
reactivity to the peptide, tetramers with both HLA-DPB1*04:01, HLA-DRB4*01:01, and 
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corresponding mouse MPO409-428 (PRWNGEKLYQEAYRKIVGAMV) were created (Figure 
3.1).  
Patient peripheral blood mononuclear cells (PBMCs) were isolated from cell preparation 
tubes (CPT, BD Biosciences), washed twice with phosphate buffered saline (PBS, Life 
Technologies) and stored in 1mL RPMI with 10% FBS at 4°C overnight. Cells were then 
counted and resuspended at 5x106/mL in RPMI with 10% FBS, blocked (Human TruStain FcX, 
Biolegend) for 10 minutes at 37°C. 5x105 cells per condition were incubated with either no 
tetramer, or 2uL of one of the following tetramers: DPB1*04:01-MPO447-461, DPB1*04:01- 
MPO435-454, DPB1*04:01-MPO447-461 scramble, DRB4*01:01-MPO447-461, DRB4*01:01-MPO435-
454, or DRB4*01:01-MPO447-461 scramble for 1 hour at 37°C. Cells were then washed, stained 
with a panel including CD4 (BioLegend, clone RPA-T4), CD8 (BioLegend, clone HIT8a), CD14 
(BioLegend, clone 63D3), CD19 (Life Technologies, clone SJ25-C1), CD25 (BioLegend, clone 
BC96), and CD127 (BioLegend, clone A019D5) or a panel including CD4 (BioLegend, clone 
RPA-T4), CD8 (BioLegend, clone HIT8a), and CD45RO (BioLegend, clone UCHL1). Cells 
were acquired on an LSRII flow cytometer (BD), and analyzed using FlowJo software (Tree 
Star). Tetramer positive cells were detected after exclusion of doublets, followed by gating on 
lymphocytes, then CD4+/CD8- cells, and tetramer positivity was set according to a no tetramer 
control for each patient (Figure 3.2). 
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Figure 3.2. Strategy for gating tetramer+ CD4+ lymphocytes. Gating includes no tetramer 
control, MPO447-461 scramble control, and HLA-DRB4 MPO435-454. Tetramer positivity gate for 
each individual was set based on the corresponding no-tetramer control. 
Cytokine Capture for IL-17A 
Cytokine capture experiments for IL-17A production were also performed on patient 
PBMCs. Staining was performed following the kit protocol (IL-17A secretion assay PE, Miltenyi 
Biotec). Briefly, cells were stained with tetramer, incubated with CytoStim (human, Miltenyi 
Biotec) for 4 hours at 37 degrees, and then stained with capture and detection antibodies, CD4, 
CD8, CD25, and CD127 before fixation and analysis on a LSRII flow cytometer (BD), and 
analyzed using FlowJo software (Tree Star). IL-17A secreting cells were detected after exclusion 
of doublets, followed by gating on lymphocytes, and CD4+/CD8- cells (Figure 3.2). Controls 
samples without stimulation and without IL-17A antibody were used to set positive thresholds 




Figure 3.3. Gating strategy for IL-17A positivity. Representative plot shows gating scheme for 
determining percentage of IL-17A secreting cells for all CD4+ and tetramer positive cells in 
patients compared to no stimulation and no antibody (α IL-17A) controls. 
 
Flow Sorting 
 Samples were prepared for flow sorting as follows; patient peripheral blood mononuclear 
cells (PBMCs) were isolated from cell preparation tubes (CPT, BD Biosciences), washed twice 
with phosphate buffered saline (PBS), counted, resuspended at 50x106/mL in RPMI with 10% 
FBS, and blocked (Human TruStain FcX, Biolegend) for 10 minutes at 37°C. PBMCs were then 
incubated with 3uL of DRB4*01:01-MPO435-454 per 30x10
6 cells for 1 hour at 37°C. Cells were 
then washed, stained with a panel including CD4 (BioLegend, clone RPA-T4), CD8 (BioLegend, 
clone HIT8a), CD14 (BioLegend, clone 63D3), CD19 (Life Technologies, clone SJ25-C1), 
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CD25 (BioLegend, clone BC96), and CD127 (BioLegend, clone A019D5). Cells were sorted 
into PBS using a Becton Dickinson FACSAria II (BSL-2) flow cytometer with a 70µm nozzle. 
RNA Isolation 
 Immediately after flow sorting, RNA was isolated from sorted T cell populations using 
RNAqueous Micro Total RNA Isolation Kit (TermoFisher Scientific), and frozen at -80°C until 
library preparation. 
TCR Sequencing 
 T cell receptor beta repertoire profiling was done with repertoire diversity measures 
adjusted for differential read coverage done as previously described (172, 173). Briefly, RNA 
quantity was assessed by bioanalyzer before processing with the SMARTer ® Human TCR a/b 
Profiling Kit (kit lot # 1512025A). Post library prep, library concentration was measured by 
Qubit 2.0 Fluorometer using the dsDNA HS Assay Kit (lot# 1910791). Qubit was calibrated 
using the dsDNA HS standards #1 and #2 (0ng/ul and 10ng/ul respectively), then samples were 
diluted 1ul in 199ul of the assay buffer and run on Qubit after the standards. Samples were then 
run on an Agilent Technologies 2200 Tapestation to determine library size in base pairs using the 
High Sensitivity D1000 screentape and associated buffer (2ul buffer:2ul sample). Samples were 
then diluted to 10nM with SMARTer ® Human TCR a/b Profiling Kit elution buffer, based on 
Qubit concentrations and pooled in equal volumes. Qubit and tapestation were repeated on the 
final pool. The pool was loaded it on to a MiSeq at the UNC High Throughput Sequencing 
Facility at 13.5pM. 
Statistical Analysis  
GraphPad Prism was used to generate figures (Version 7, GraphPad Software, La Jolla, 
CA). For T cell receptor Beta (TRB) analysis, amplicon read quality was assessed using FastQC, 
indicating read counts and Phred scores were comparable for all samples with all samples having 
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over 250K reads. TRB clones were aligned and assembled using MiXCR 2.1.9 (174) with imgt 
library version 201802-5 (175). Diveristy metrics were calculated on the nucleotide sequnce of 
Complementarity-Determining Region 3 (CDR3) of productive clones. Uncorrected diversity 
metrics included Abundance (read counts for a clone), Richness (number of unique clones), 
Shannon Entropy (calculated in R (176)  using vegan::diversity (177) and Evenness (Shannon 
Entropy / Log Richness). The following normalized diversity metrics were calculated using 
VDJTools (178) to bootstrap counts 100x to the lowest number of aligned reads for all samples: 
Observed Diversity, Shannon-Wiener, Normalized Shannon-Wiener and d50. VDJTools was 
also used to exprapolate species number out to the highest read count (ChaoE) and asymptotic 
diversity (Chao1 and Efron-Thisted).  Diversity metrics were compared using a T-Test for two 
group comparison and an ANOVA for more than two groups. Patient Identity was taken into 
account for these comparisons. False Discovery Rate corrections were done using the Benjamini-
Hochberg method (179) using R ((176); stats::p.adjust).  Morisita Horn Similarity Indices were 
performed on the amino acid CDR3 sequence of productive clones using the 'horn' method (180) 
of vegan::vegdist (177). The Morisita-Horn Dissimilarity Indices were subtracted from one to get 
the Similarity Indices presented. T-Tests were used to compare differences in these Indices 
between groups. Graphs were made using ggplot2 (181). 
Results 
MHC II tetramers identify patient autoreactive CD4+ T cells 
MHC II tetramers were used to investigate epitope specificity of autoreactive CD4+ T 
cells in patients with MPO-ANCA vasculitis. While some patients had low responses across all 
tetramers (Figures 3.4A-3.4F), greater reactivity was demonstrated in response to MPO435-454 
with both HLA-DPB1*04:01 and HLA-DRB4*01:01 (Figure 3.4A & 3.4D), and a decreased, but 
still positive, response to MPO447-461 in the HLA-DPB1*04:01 tetramer (Figure 3.4E) compared 
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to controls. Overall, healthy controls and patients who do not carry the corresponding HLA had 
low or undetectable tetramer binding (Figure 3.4A-F, HLA-DPB1 alleles other than *04:01 for 
null and heterozygous patients shown in Table 3.2). 
Figure 3.4. Patients demonstrate HLA and epitope specific tetramer recognition by CD4+ T 
cells. (A-F) CD4+ T cell recognition of tetramers in MPO-ANCA patients (n=20), ANCA 
negative patients (n=3), and healthy controls (n=5). Dashed grey line indicates threshold of 
positivity determined by the average plus two standard deviations of healthy control and null 
patient tetramer positivity. (A) HLA-DRB4*01:01 tetramer carrying MPO435-454 (B) HLA-
DRB4*01:01 tetramers carrying MPO447-461 (C) HLA-DRB4*01:01 tetramer carrying MPO447-461
scramble control. (D) HLA-DPB1*04:01 tetramer carrying MPO435-454 (E) HLA-DPB1*04:01 
tetramer carrying MPO447-461 (F) HLA-DPB1*04:01 tetramer carrying MPO447-461 scramble 
control.  
When comparing reactivity of patient CD4+ T cells to human MPO435-454 and mouse 
MPO409-428 using HLA-DPB1*04:01 tetramers, we found consistently higher reactivity to the 
human epitope (Figure 3.5A). In contrast, some patients demonstrate more CD4+ T cell reactivity 
to HLA-DRB4*01:01 tetramers carrying mouse MPO409-428 than human MPO435-454, while others 
had minimal reactivity to both tetramers (Figure 3.5B). This again demonstrates that CD4+ T cell 




Figure 3.5. Epitope specificity of Patient CD4+ tetramer binding. Patient CD4+ T cells 
preferentially bind human MPO435-454 over mouse MPO MPO409-428 when presented with HLA-
DPB1*04:01, but not with HLA-DRB4*01:01. (A) Comparison of patient (n=4) CD4+ T cell 
recognition of HLA-DPB1*04:01 tetramers carrying human MPO435-454 or mouse MPO409-428. 
(B) Comparison of patient (n=7) CD4+ T cell recognition of HLA-DRB4*01:01 tetramers 
carrying human MPO435-454 or mouse MPO409-428. 
 
To further investigate the specificity of tetramer binding, dual tetramer staining was 
performed with the B cell epitope (DPB1*04:01-PE-MPO447-461) and the T cell epitope 
(DPB1*04:01-PE/Cy5-MPO435-454) loaded in the same HLA. We found that nearly all tetramer 
positive cells were positive for both tetramers (Figure 3.6), suggesting that the overlapping 
region of these epitopes may be required for binding to HLA. This supposition is also supported 
by the open binding pocket structure of MHC II receptors that allows for variable length epitope 
binding but relies on nine core residues (182).  
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Figure 3.6. Dual staining reveals dual binding ability of patient CD4+ T cells. Dual staining with 
DPB1*04:01 PE-MPO447-461 and PE Cy5-MPO434-454 tetramers day 1 ex-vivo. Plot shows n=4 
patients concatenated due to low tetramer positivity of patient CD4+ T cells.  
Autoreactive CD4+ T cells are enriched for CD25intermediate memory effector cells 
Tetramer positive CD4+ T cells were further characterized for CD25 and CD127 
expression and a significant portion of tetramer positive cells were CD25intermediateCD127+ cells 
(13.3%-77.4% across all tetramers, 44.7% average for MPO447-461, 49.6% average for MPO435-
454), as previously described (Figure 3.7) (105). 
Tetramer positive cells were also assessed for the presence of memory marker CD45RO 
on their surface. Consistently greater than 50% of the tetramer positive population expressed 
memory marker CD45RO (60% average across all tetramers). This is consistent with a previous 




Figure 3.7. Patient CD4+ T cells that bind tetramers are enriched for CD25intermediate cells. (A) 
Gating strategy for CD25intermediate cells using a representative patient. Consistently half of 
tetramer positive cells were CD25intermediate T cells (n=14). 
 
 
Figure 3.8. Patient CD4+ T cells that bind tetramers are enriched for memory marker CD45RO. 
Representative plot demonstrating that the expression of CD45RO+ was slightly higher in 
tetramer positive cells than overall CD4+ T cells. 
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Autoreactive CD4+ T cells secrete IL-17A 
Based on previous reports of cytokine secretion in autoimmunity and ANCA vasculitis, 
we investigated the ability of patient autoreactive CD4+ T cells to secrete IL-17A (105, 156, 
157). We compared IL-17A secretion of tetramer positive CD4+ T cells to IL-17A secretion by 
total CD4+ T cells in each patient. For these studies, tetramers with both HLA-DPB1 and HLA-
DRB4 carrying the T cell epitope MPO435-454 were used. A higher proportion of tetramer positive 
cells secreted IL-17A in response to stimulation than total CD4+ T cells for each patient 
regardless of HLA restriction, confirming the pro-inflammatory ability of the autoreactive CD4+ 
T cells (Figure 3.9). 
Figure 3.9. Patient CD4+ T cells that bind tetramers are pro-inflammatory cells that secrete IL-
17A. Compared to all CD4+ T cells, a higher proportion of tetramer positive CD4+ T cells secrete 
IL-17A in patients for both HLA-DPB1*04:01 and HLA-DRB4*01:01 (n=8). Patients included 
in experiments were either Hom = homozygous, Hz = heterozygous for HLA-
DPB1*04:01/HLA-DRB4*01:01. 
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Autoreactive CD4+ T cells are clonally restricted compared to controls 
We next sought to understand whether MPO435-454 specific T cells showed evidence of 
clonal expansion relative to the tetramer negative, CD25intermediate, CD25-, and regulatory T cell 
populations. Utilizing the MiSeq platform, we analyzed the TCR repertoires of four FACS sorted 
T cell populations (tetramer+, CD25intermediate, CD25-, and Tregs). The HLA-DRB4*01:01 
tetramer carrying MPO435-454 was used exclusively for these experiments based on consistent 
patient reactivity to it (Figure 1D), to collect as many cells as possible from the rare tetramer 
positive population. HLA-DRB4*01:01-MPO435-454 specific T cell receptor repertoires showed 
decreased species richness, Shannon entropy, and d50 indices, consistent with diminished T cell 
receptor repertoire diversity in the antigen-specific T cell population compared to all controls 
(Figure 3.10A). Interestingly, we also observed a decrease in TCR repertoire diversity in the 
CD25intermediate memory effector cells compared to naïve CD25- T cells. Treg diversity was not 
different from memory CD25intermediate T cells, but was decreased compared to CD25- naïve T 
cells. Importantly, matched uncorrected (Abundance, Richness, Shannon Entropy, Evenness, 
Figure 3.10B) and matched extrapolated (ChaoE, Chao1, Efron Thisted, Figure 3.10C) diversity 
measures replicated the same patterns of diversity between populations as the matched 
bootstrapped diversity measures. These results suggest increased clonal expansion of MPO 
reactive CD4+ T cells compared to unselected CD25intermediate memory, CD25- naïve, and 








































































































































































































































































































































































































































































































TCR sequencing reveals some public TCR clones 
We also investigated T cell receptor Beta (TRB) clonotype similarity between patients to 
identify any public TCR clones. Although we do not see any TCR sharing between the antigen 
selected tetramer positive cell populations in patients as we predicted (Figure 3.11), we do see 
some TCR sharing within the CD25- naïve T cell populations of two patients (Figure 3.11A). 
Similarly, we see less but still some TCR sharing between two different patients within the 
CD25intermediate population (Figure 3.11B). Considering that these cells were not selected for 
antigen reactivity, the vast diversity of possible TCR arrangements, and that both patients have 
MPO-ANCA vasculitis, it is highly unlikely that these public TCRs are due to chance. These 
results suggest T cell dysregulation in patients beyond MPO antigen specificity of TCRs.  
In addition to pairwise TRB colonotype similarity comparisons, we performed population 
comparisons for TRB subunit frequency. T cell receptor beta variable (TRBV) analysis reveals a 
trend toward decreased TRBV6-2 subunit usage in both tetramer positive and Treg populations, 
and increased TRBV6-3 subunit usage in both tetramer positive and Treg populations compared 
to CD25- naive and CD25intermediate T cell populations (Figure 3.12). It is possible that these 
differences indicate a shift from TRBV6-2 to TRBV6-3 usage in the tetramer positive and 
regulatory T cell populations in patients with MPO-ANCA vasculitis. We also assessed T cell 
receptor beta joining (TRBJ) subunit frequency and found no differences between tetramer 
positive cells and control T cell populations (Figure 3.13). This result is not surprising given the 
limited number of joining (J) gene segments.  
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Figure 3.11. Clonotype population comparison reveals CD25- naive and CD25intermediate memory 
T cell clones shared between two patients. Comparison of tetramer positive and control T cell 
clonotype populations in n=5 patients (n=4 for tetramer and Treg samples). (A) comparison of 
tetramer positive and CD25- naive T cell clonotypes (B) comparison of tetramer positive and 
CD25intermediate memory T cell clonotypes and (C) comparison of tetramer positive and regulatory 
T cell clonotypes. Note that similarity index colors are consistent between plots while similarity 




































































































































































Figure 3.13. TRBJ subunit frequency analysis reveals no differences in joining subunit usage 
between tetramer positive cells and control T cell populations. 
Discussion 
Studies using MHC class II tetramers demonstrated that patients with HLA-DPB1*04:01, 
HLA-DRB4*01:01, or both, have CD4+ T cells that recognize and bind specific regions of MPO 
(specifically B cell epitope MPO447-461 and/or T cell epitope MPO435-454) when stained directly ex 
vivo without stimulation. HLA-DPB1*04:01 and HLA-DRB4*01:01 were chosen for tetramer 
analysis based on binding to the epitopes of interest during in vitro studies and their prevalence 
in our patient cohort. Our ability to detect measurable frequencies of tetramer positive CD4+ T 
cells directly ex vivo suggests chronic autoantigen exposure in vivo to maintain these 
autoreactive cells at detectable levels.  
Approximately half of the tetramer positive CD4+ T cells were CD25intermediateCD127+ 
cells, which suggests that these may be activated effector memory cells, a conclusion further 
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supported by positivity for memory marker CD45RO. We also assessed IL-17A secretion of 
patient T cells based on results from previous work that demonstrated increased IL-17A, 
increased IL-4, and unchanged interferon gamma (IFN-γ) secretion from CD25intermediate cells 
compared to control CD4+ T cells in patients (105). When compared to overall CD4+ T cells, a 
higher proportion of tetramer positive cells secrete IL-17A upon stimulation suggesting that 
these autoreactive cells are primed and poised to respond in a pro-inflammatory manner. 
Together, these results suggest that tetramer positive CD25intermediate T cells are autoreactive cells 
that play a role in the immunopathogenesis of MPO-ANCA vasculitis. 
Additionally, dual positivity of the HLA-DPB1*04:01 tetramers suggests the overlapping 
region between these two epitopes may contain the most important residues for immune 
recognition in patients with HLA-DPB1*04:01. It is also possible that this dual staining is 
explained by non-specific binding of these tetramers, though the difference in T cell binding to 
HLA-DPB1*04:01 tetramers with the mouse and human versions of the T cell epitope (Figure 
3.5A) makes this explanation less likely. 
TCR sequencing revealed decreased diversity of the autoreactive CD4+ TCR repertoire 
compared to CD25intermediate, CD25-, and regulatory T cell controls, which supports chronic 
antigen exposure leading to clonal expansion of the autoreactive cells in patients. This stepwise 
decrease in diversity from CD25- naïve cells, to CD25 intermediate memory cells, to our MPO435-454
reactive cells underscores the specificity of this CD4+ T cell response to MPO. Interestingly, the 
regulatory T cell population is most similar to CD25intermediate cells with regard to TCR diversity. 
Population TCR comparisons revealed some receptor sharing between patients, though not in the 
tetramer positive population of cells. One explanation is that we are missing existing tetramer 
positive cells with public TCR clones located at sites of inflammation because we are sampling 
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CD4+ T cells from peripheral blood. Another possible explanation is that patient autoreactive 
CD4+ T cells start as a diverse population of cells with shared clones between patients, but that 
different cells end up clonally expanding in different patients, narrowing the repertoire and 
masking any sharing upon analysis. Finally, TRBV analysis reveals a shift in TRBV6-2 to 
TRBV6-3 subunit usage in tetramer+ and regulatory T cells, but not in CD25- naïve or 
CD25intermediate T cell populations. Though not significant, if this shift is present in additional 
patients, it may reveal a role for TRBV subunit usage in that pathogenesis of MPO-ANCA 
vasculitis. 
These surface staining and TCR sequencing experiments reveal some markers of CD4+ T 
cell autoreactivity in patients, though they do not identify a unique autoreactivity signature. 
Additional experiments including RNA sequencing of tetramer positive cells and control 
populations may reveal other markers in this signature. Eventually, this signature can be used to 
develop CAR T cells that specifically target autoreactive cells. For now, this work provides new 
insight into the interactions between HLA, antigenic peptides, and the CD4+ T cell-mediated 
adaptive immune response that will inform the development of these new therapies for patients 
with MPO-ANCA vasculitis and other autoimmune diseases.  
Summary 
 The presented body of work focused on the interactions between autoreactive cells and 
pathogenic epitopes in ANCA vasculitis. Chapter 1 assessed HLA sequence based typing of a 
large cohort (n=249) of patients with ANCA vasculitis and revealed, contrary to previous 
reports, that carriage of HLA-DPB1*04:01 does not increase risk of relapse in a combined (MPO 
and PR3-ANCA) cohort. Additionally, this analysis identified HLA-DPB1*04:01 and HLA-
DRB4*01:01 as highly represented alleles in our cohort of MPO-ANCA vasculitis patients. This 
chapter also included a discussion of the differences between MPO and PR3 ANCA-vasculitis 
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and reasons for studying pathogenic epitopes and autoreactive cells for each serotype 
independently. 
Chapter 2 investigated previously identified epitopes MPO447-461 and MPO435-454 for 
patient autoantibody reactivity, binding to MHC receptors, structural characteristics, and solvent 
exposure. These studies showed that MPO447-461 and MPO435-454 are located on the same alpha 
helix, that this alpha helical structure is required for anti-MPO447-461 binding, and that MPO447-461 
is buried while MPO435-454 is exposed to solvent. Additionally, ELISA studies revealed that 53% 
of patients have anti-MPO447-461 antibodies, most often at onset. Finally, in vitro binding studies 
confirmed the ability of MPO447-461, MPO435-454, and a scrambled control epitope to bind HLA-
DPB1*04:01 and HLA-DRB4*01:01.  
Chapter 3 combined knowledge from chapters 1 and 2 to create HLA-DPB1*04:01 and 
HLA-DRB4*01:01 tetramers carrying MPO447-461 and MPO435-454 and a scrambled control. 
Studies using these tetramers identified autoreactive CD4+ T cells in patients that were pro-
inflammatory (IL-17 secretion), memory (CD45RO expression), CD25intermediate cells. TCR 
sequencing revealed increased clonal expansion of tetramer positive autoreactive cells compared 
to naïve and memory T cell controls from the same patient. TRB analysis also revealed some 
shared clones between patient CD25- and CD25intermediate T cell populations and altered TRBV 
subunit frequency in tetramer+ and regulatory CD4+ T cell populations. These data further 
implicate CD4+ T cells in the etiology and pathogenesis of MPO-ANCA vasculitis and provide 
targets for the development new therapies.  
Taken together, these results elucidate the specific interaction between B and CD4+ T 
cells and MPO epitopes in patients with MPO-ANCA vasculitis. We characterized each piece of 
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the cell-mediated adaptive immune response including MHC receptor, peptide, and TCR to 
better understand the loss of immune tolerance in our patients. Ideally, these discoveries will 
pave the way to antigen-specific therapies and improved quality of life for patients suffering 





EPILOGUE: RESTRICTED EPITOPE RECOGNITION IN PATIENTS WITH MPO-
ANCA VASCULITIS 
Considering the significant homology between human and mouse whole MPO (86.5% 
identical, 94.4% similar), the minor amino acid differences between this region in mouse and 
human MPO supports the hypothesis that autoantigens reside in highly conserved domains (183). 
This region of MPO also fits the hypothesis that many important autoantigens are enzymes 
engaged in important biological functions, and that the immune response is often directed at the 
active/catalytic site of the antigen (184). While this region of interest does not fall directly 
adjacent to the active site of MPO, based on the crystal structure of human MPO, MPO447-461 is 
adjacent to an alpha helix that stabilizes the active site and interacts with the implicated alpha 
helix via a hydrogen bond and hydrophobic residues (Figure E.1).  
 
Figure E.1. MPO435-461 in relation to the active site of MPO. Interactions between MPO435-461 
(blue) and the neighboring alpha helix that stabilizes the active site (red) include multiple 




Given that the B cell epitope MPO447-461 is buried within MPO, the structure of MPO 
must be substantially disrupted to facilitate an IgG-directed immune response to this epitope in 
patients. The location of this epitope in proximity to the active site of MPO suggests that a 
substantial structural disruption that would make MPO447-461 accessible to the immune system 
would likely also disturb the active site. The events leading to this disruption of MPO that reveal 
buried epitopes to the immune system may be equally as important for the autoimmune process 
as the presence of autoreactive cells. Possible explanations for this structural disruption include 
misfolding and/or protease cleavage of MPO, possibly due to overexpression in patient 
neutrophils. This is an intriguing possibility because the epitope for anti-glomerular basement 
membrane (GBM) antibodies is also buried and requires conformational changes of the antigen 
to be revealed (146).  
Of the twelve patients included in both tetramer and ELISA studies, half with ANCA 
reactivity to MPO447-461 by ELISA also demonstrated tetramer reactivity to at least one peptide 
from the same MPO region. Therefore, this region of MPO contains overlapping B and T cell 
epitopes. This is important to consider for the development of future therapies designed to induce 
tolerance using T cell epitopes as they may lead to an unintentional autoantibody response in 
patients. While overlapping B and T cell epitopes have been reported in infection (185, 186), 
other studies have reported that separate, although often adjacent, epitopes are required for 
efficient B and T cell collaboration (187). These data combined with previously reported 
immunogenicity in mice suggest an important role for overlapping MPO epitopes in the 




While it is clear that the region of MPO we chose to assess is involved in disease 
immunopathogenesis, there may be other pathogenic regions. Previous studies demonstrated 
autoantibody reactivity to other regions of MPO on both the light (52) and heavy chains (49, 51, 
53-55). One study, Fujii et al., used recombinant deletion mutations within specific regions of 
MPO to identify B and T cell epitopes and found some recognition of this region (Hc; MPO409-
474), but higher reactivity to other regions of the heavy chain of MPO (Ha; MPO279-341, Hb; 
MPO341-409, and Hg; MPO598-745) (56). Although epitopes within the region MPO435-461 have been 
implicated in disease immunopathogenesis for some patients, there may be a combinatorial effect 
with other HLA-peptide combinations, and some patients may have reactivity to other regions of 
MPO exclusively. It is also possible that patients have T cell autoreactivity to conformational 
(non-continuous) epitopes, though identification and confirmation of these epitopes is technically 
very challenging. Importantly, one group has demonstrated evidence that nasal insufflation of an 
epitope in this region induced tolerance to whole MPO in a mouse model of ANCA vasculitis 
(115), so it is possible to restore immune tolerance to an entire autoantigen with the use of a 
single pathogenic epitope.  
Future Directions  
The studies reported here examine immune reactivity to one very specific piece of MPO. 
As described above, other regions of MPO have been implicated in disease and should be 
investigated. Additionally, the studies presented here reveal additional HLA-peptide 
combinations of interest that should be investigated. For example, HLA-DQ alleles have been 
associated with MPO-ANCA vasculitis in multiple GWAS studies (59, 70) and our in silico and 
in vitro binding studies identified MPO105-119 as a potential binding partner. However, it is clear 
that MPO435-461 plays a role in disease pathogenesis. The results presented here inform the design 
of antigen specific therapies using epitopes in this region to reintroduce tolerance in disease. Gan 
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et al. demonstrated disease amelioration with nasal insufflation of a peptide in this region in a 
mouse model of ANCA vasculitis immunopathogenesis (115). Additionally, tolerogenic 
dendritic cell therapies are now in clinical trials for some autoimmune diseases (120, 121). New 
treatments that harness nanoparticle presentation of antigen, tolerogenic dendritic cell 
presentation of antigen, or antigen targeted cells should be pursued using this region of MPO in 
pursuit of better therapies for patients with MPO-ANCA vasculitis.  
Another aspect of the autoimmune response in ANCA vasculitis that we have yet to 
investigate is the role of CD8+ cytotoxic lymphocytes. Similar in silico binding predictions, in 
vitro binding studies, and tetramer studies may be performed using MHC I tetramers to identify 
antigenic regions of MPO that patient CD8+ T cells are recognizing. Studies in mice have 
demonstrated the pathogenic potential of CD8+ T cells in a model of anti-MPO 
glomerulonephritis and identified a pathogenic CD8+ T cell epitope MPO431-439, which 
corresponds to human MPO457-465 and overlaps with our B cell epitope MPO447-461 (139). It is 
definitely worth investigating patient CD8+ T cell reactivity to this region in patients with MPO-
ANCA vasculitis. 
These studies do not address the relationship between T cell autoreactivity to MPO435-461 
and disease activity. This may be addressed in future studies using paired samples from patients 
at times of active disease and remission, or cross-sectionally with a large cohort including 
patients in disease remission and with active disease. These studies also raise the question of how 
immunosuppressive medication alters the presence of autoreactive cells. While some of the 
patients in our cohort were in remission and untreated for a year or more, every patient used for 
the tetramer studies has a history of at least some immunosuppressive therapy. Although 
performing these studies in new onset ANCA vasculitis patients prior to therapy is ideal, the 
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need for high-resolution HLA typing information makes tetramer experiments technically 
unattainable unless patients have been typed prior to disease onset and tetramers are available. 
Studies to assess the effects of common immunosuppressive medication on tetramer reactivity 
may be informative in this case.  
Flow cytometry is a powerful tool that has greatly increased our understanding of 
immune cell subsets since it was first developed. However, the technique is limited by 
fluorophore spectral overlap, which restricts the number of markers that can be assessed at any 
given time in one population of cells. It is also a targeted method where surface markers of 
interest are determined before doing the experiment. In contrast, RNA sequencing of cells 
provides an unbiased look at the expression of all genes within specific populations of cells. The 
sheer number of cells that needed to be sequenced for informative gene expression data once 
limited the practicality of this method, but technological advancements now allow efficient 
sequencing of rare cell populations. RNA sequencing can reveal heterogeneity within cell 
populations that share the same surface markers but have different gene expression profiles, or it 
can be used to identify similarities between seemingly diverse populations of cells. For example, 
this technique identified a signature that distinguishes populations of Th17 cells, which can be 
pathogenic or non-pathogenic depending on cytokines in the environment during cell 
polarization (188). In this case, we can use this technique to identify similarities within a 
potentially diverse population of autoreactive cells. Defining a unique “autoreactive signature” 
will increase our understanding of how and why autoreactive CD4+ T cells escape regulation in 
the periphery of patients. 
Finally, studies of PR3-ANCA vasculitis have been hindered by a lack of animal models 
of disease (138). Ultimately analysis of MHC-peptide-TCR interactions described in this 
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dissertation should be performed for previously identified regions of both PR3 and 
complementary PR3. If patient CD4+ T cells react to specific regions of complementary PR3, it 
may help narrow the search for the proposed infectious molecular mimic that causes disease 
induction. Given GWAS and HLA sequencing identification of HLA-DPB1*04:01 as a risk 
allele for patients with PR3-ANCA vasculitis (1, 59, 69, 70), and our results from chapter 1 that 
suggest carrier risk for PR3-ANCA vasculitis patients, pursuing epitopes predicted to bind this 
HLA will likely yield epitopes of interest. Due to the epitope specificity in most patients, 
therapies designed to reintroduce tolerance in patients with MPO-ANCA vasculitis will likely 
not be effective for patients with PR3-ANCA vasculitis, though the same methods may be 
effective for both. Therefore, it is imperative to identify pathogenic regions of PR3 that will 
inform development of new antigen specific therapies for patients with PR3-ANCA vasculitis.  
Conclusions  
This field is rapidly moving toward the use of antigen-specific therapies that either 
reintroduce immune tolerance using pathogenic autoantigen epitopes, or target antigen specific 
autoreactive cells. However, embarking on this quest requires a thorough understanding of the 
interaction between HLA, autoantigen peptides, and autoreactive B and T cells for each 
autoimmune disease. Here I identified and characterized the specific interactions between MHC 
II receptors, MPO epitopes, and CD4+ TCRs that occur in patients with MPO-ANCA vasculitis. 
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